

SESSIONS

ABD COURSE (NOV 1-3, 2024)

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Course Format

07:30 - 08:30

The Advanced Business Development course is instructed by experienced dealmakers and industry experts. It's a blend of lectures and also incorporates Case Studies, which include a mock valuation, negotiation and deal making exercise designed to apply concepts learned during the course and challenge participants. The Case Study is often cited as the participant's favorite part of the course.

The course is instructed by Joe Dillon, Lesley Stolz, Patrick Duxbury, and Kenneth Krisko. View the course leader's [bios](#) here.

Course will take place: **November 1–3, 2024**

Location: **Scandic Continental** (Vasagatan 22, 111 20 Stockholm)

Three-Day Course Schedule

Friday, November 1, 8:30 a.m. - 6:00 p.m. CET
(Inclusive of Evening Networking Reception)

Saturday, November 2, 8:30 a.m. - 5:45 p.m. CET

Sunday, November 3, 8:30 a.m. - 5:00 p.m. CET

Day One - Valuation and Deal Structuring Skills - Friday, November 1

08:30 - 18:00

Advanced Business Development Course - Nov 1

Topics covered:

- Valuation and Deals Structuring Concepts and Trends
- Valuation Methodologies, Techniques and Major Factors
- Case Study Work & Break Out Sessions
- Forecasting, Analysis and Decision-support
- Deal Structuring and Terms

5 - 6pm: *Evening Networking Reception*

Day Two - Negotiation Strategies and Intellectual Property - Saturday, November 2

08:30 - 17:45

Advanced Business Development Course - Nov 2

Topics covered:

- Negotiation Preparation
- Case Study Work
- Managing the Process and Influence Strategies
- Types of IP, Freedom to Operate, Issues in Due Diligence
- Creating a Protection Timeline, Research Exemption, Competition Law

Day Three - Contracts and Case Study Wrap-up - Sunday, November 3

08:30 - 17:00

Advanced Business Development Course - Nov 3

Topics covered:

- Key Concepts and Building Blocks of a Block Buster Deal
- Select Topics of Advanced Deal Structures
- Trap Doors, Dead Ends, and other Do's and Don'ts
- Current Trends in Licensing Deals
- Case Study Completion
- Case Study Review

SCHEDULE

ABD COURSE (NOV 1-3, 2024) -

BIO-Europe
Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	ADVANCED BUSINESS DEVELOPMENT COURSE - NOV 1	ADVANCED BUSINESS DEVELOPMENT COURSE - NOV 2	ADVANCED BUSINESS DEVELOPMENT COURSE - NOV 3
07:00	07:30 - Course Format	07:30 - Course Format	07:30 - Course Format
08:00	08:30 - Day One - Valuation and Deal Structuring Skills - Friday, November 1	08:30 - Day Two - Negotiation Strategies and Intellectual Property - Saturday, November 2	08:30 - Day Three - Contracts and Case Study Wrap-up - Sunday, November 3

SESSIONS

PRE-EVENT ACTIVITIES (NOV 3) - 03/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Pre-event registration and badge pick up (14:00 – 19:00)

13:30 - 14:00

Time: 14:00- 19:00 CET

Location: **Stockholmsmässan**

Mässvägen 1,

125 30 Älvsjö,

Sweden

<https://maps.app.goo.gl/2GTgMmQo9dUzZ4qP8>

Explore Stockholm with a Nobel Twist

14:00 - 16:30

Stockholm Tour 1

Join us for a guided walk through the charming alleys and streets of Gamla Stan, which is Stockholm's beautifully preserved Old Town. Our walk will take us past the Swedish Parliament buildings and the Royal Palace.

Meeting point: Sheraton Stockholm Hotel

[Join the Wait List](#)

Experience an exclusive afternoon tour to Uppsala

14:00 - 17:00

Stockholm Tour 2

Uppsala has a one-of-a-kind eco-system for innovation and commercialization with its two Universities, Uppsala University and the Swedish University of Agricultural Sciences. You will get the opportunity to visit the innovation hub Testa Center and its hosting company Cytiva with its state-of-the-art labs and equipment. In addition, spearheading academic research groups will present their latest research.

Meeting point: Radisson Blu Waterfront Hotel

[Sign up here](#)

Hagastaden, Stockholm's world-class Life Science district

14:00 - 17:00

Stockholm Tour 3

Join us for a guided tour of Karolinska University Hospital followed by Karolinska Institutet, SciLifeLab and Nobel Forum. Then meet with some of the key opinion leaders at A Working Lab Innomedicum, next to Karolinska Institutet, presenting on various topics.

Meeting point: Karolinska University Hospital, Main Entrance

[Join the Wait List](#)

Newcomer's Program

17:00 - 18:30

Newcomer's Program

Is this your first BIO-Europe? Eager to get a head start with your networking? Join the BIO-Europe Newcomer's session the day before the conference starts to learn best practices to maximize your partnering onsite, how to coordinate partnering with your chosen program sessions, and enjoy a chance to mix and mingle with other first timers.

Location: BIO-Europe Conference Venue, Stockholmsmässan

Fully Booked

BIO-Europe Welcome Reception

19:00 - 21:00

BIO-EUROPE WELCOME RECEPTION

The City of Stockholm invites BIO-Europe to a networking reception in the City Hall's stunning Blue and Golden Halls. Designed by architect Ragnar Östberg, Stockholm City Hall is a prominent example of the Swedish Romantic style and one of the city's most visited tourist attractions. The ceremonial halls hold unique art pieces that reference events in Stockholm's history.

This special venue has requirements in place that are intended to manage large numbers of people, in order to ensure a safe and comfortable experience. **Advance sign-up, independent from your conference registration, is therefore required for the reception.**

The Welcome Reception has seen unprecedented demand and is currently *FULLY SUBSCRIBED*.

You must also have your conference badge with you to enter the City Hall. Please note that **badge collection is not available at the City Hall.**

Badge pick up for **Sunday** is available at **two locations**:

- Stockholmsmässan (the conference venue) 14:00 – 19:00 CET
- Sheraton Stockholm Hotel (near the Central Station and City Centre hotels) 14:00 – 20:30 CET (Badge pick up only. No new onsite registrations possible at this location.)

Location: Stockholm City Hall

Venue address:

Hantverkargatan 1

111 52 Stockholm, Sweden

SCHEDULE

PRE-EVENT ACTIVITES (NOV 3) - 03/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	STOCKHOLM TOUR 1	STOCKHOLM TOUR 2	STOCKHOLM TOUR 3	NEWCOMER'S PROGRAM	BIO-EUROPE WELCOME RECEPTION
13:00	13:30 - Pre-event registration and badge pick up (14:00 – 19:00)	13:30 - Pre-event registration and badge pick up (14:00 – 19:00)	13:30 - Pre-event registration and badge pick up (14:00 – 19:00)	13:30 - Pre-event registration and badge pick up (14:00 – 19:00)	13:30 - Pre-event registration and badge pick up (14:00 – 19:00)
14:00	14:00 - Explore Stockholm with a Nobel Twist	14:00 - Experience an exclusive afternoon tour to Uppsala	14:00 - Hagastaden, Stockholm's world-class Life Science district		
17:00				17:00 - Newcomer's Program	
19:00					19:00 - BIO-Europe Welcome Reception

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

BiotechBikers Spin Session

06:30 - 07:30

When: Monday, November 4, 6:30am - 9:30am (approx.)

Where: [Studio l'Echelon](#)

What: Join BiotechBikers for an instructor-led indoor spinning session followed by a chance to network over breakfast.

- Arrive from 6:30am
- Private spinning session with an instructor, 7-8am
- Showers, change, and breakfast networking 8-9.30am

Fully Booked

Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)

07:45 - 08:00

Location: **Stockholmsmässan**

Light Breakfast: **served until 10:45**

Partnering: one-to-one meetings (9:00 - 18:30 CET)

08:00 - 08:30

One-to-one meetings at BIO-Europe will be scheduled during the hours below:

Meetings on this day will start at **9:00 – 18:30 CET**.

Buzz Session: Winning Presentations, Influencing Partnerships

08:30 - 10:00

Relax and Learn.

Location: Room K18

This session is an interactive workshop which aims to provide participants with practical tools, ideas and best practices to consider when creating and structuring your pitch presentations. It also dives into understanding how to enhance your professional behaviour and tap into your emotional intelligence when in pitching, partnering and negotiating situations, to lead to successful long-term partnerships.

Agenda:

Part 1 – Your presentation sets a precedent for partnership

- Influence or educate?
- Utilising Aristotle's four rhetorical appeals
- Tuning in to others' pains and gains

Part 2 - What's your point?

- Preparing your most compelling message
- Less is more
- What do you want them to take away?

Part 3 – Packaging a winning presentation

- Opening for attention
- A powerful structure to reinforce your key messages
- Closing for impact

Participants

Trainer: **Simon Fagg** - Founder, With Leadership

partneringONE essentials workshop

09:30 - 10:00

Relax and Learn

Location: Room K12

This interactive workshop is for delegates new to partnering. What can you expect from partnering, and what do others expect from you? Principles around timing, human nature, and partnering etiquette will be applied to the partneringONE process. This session will give you a clear understanding of tactics to generate the best ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have. This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can't attend a session, drop by the partnering help desk with any questions.

Participants

Speaker: **Jordan Stillman** - Project Manager, partneringOne

"The Way Old Friends Do": Opening remarks

10:00 - 10:30

Business of Biotech

Location: Room K1/K2

Participants

Panelist: **Claire Macht** - Portfolio Director, Europe, EBD Group

Panelist: **Ebba Busch** - Minister for Energy, Business and Industry and Deputy Prime Minister, Government of Sweden

Panelist: **Karin Wanngård** - Mayor, City of Stockholm

Panelist: **Chad Wessel** - Director, Industry Analysis, Biotechnology Innovation Organization (BIO)

"Super Trouper": The entrepreneurial magic

10:30 - 11:00

Business of Biotech

Location: Room K1/K2

Insights from world-leading scientist and serial Entrepreneur. What does the next 30 years look like?

Participants

Moderator: **Ylva Williams** - CEO, Stockholm Science City Foundation

Panelist: **Mathias Uhlen** - Professor KTH and KI, SciLifeLab

"Voulez-Vous?": Investing in a sustainable future with global pharma

11:00 - 11:30

Business of Biotech

Location: Room K1/K2

Learn about the pharmaceutical industry's carbon footprint and delve into its efforts towards investing in sustainable practices. Explore innovative approaches, best practices, and the potential of implementing circular economy principles, to drive long-term growth whilst addressing environmental and social responsibilities. Join us to uncover how the industry is shaping a healthier and more sustainable future.

Participants

Moderator: **Britta Stenson** - Head of Global Industry Network Life Science, Business Sweden

Panelist: **Magnus Bjorsne** - Executive Director AZ BioVenture Innovation Unit, CEO AZ BioVentureHub AB, AstraZeneca

Panelist: **Lauri Lehtovuori** - Founder & CEO, Combient Foundry

Panelist: **Malin Parkler** - VD, Country Manager Sweden, Pfizer

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Lunch

12:00 - 14:00
Lunch

"Listen to Your Heart": Navigating the wild path - Nordic leaders raising the ceiling for women

12:00 - 12:45
Ecosystem Innovation

Location: Exhibit Hall Stage

Explore the complexities of gender equality in the Nordic region. While the Nordics have made significant strides in comparison to other regions, taking a closer look reveals that challenges remain. Join this session to discover the challenges that still exist and understand the importance of the need for continuous advocacy, despite the significant progress made.

Targeting three key groups: the seasoned female leader, men and the up-and-coming generation of female leaders, the session celebrates the contributions in setting the ceiling for future generations to walk on, why and how men should get involved, inclusively, and the current experience of today's generation of female leaders.

Participants

Moderator: Hans T. Schambye - Chair of Dansk Biotech, CEO & President of Galecto, Galecto

Panelist: Markus Dietrich - Senior Investment Associate at Hadean Ventures & Ambassador in Wild Norway, Hadean Ventures

Panelist: Lene Gerlach - Founder & Chair, Women in Life Science Denmark (WiLD)

Panelist: Christina Lloyd - Chairwoman, VILDA Sverige

Panelist: Chelsea Ranger - Founder & Chair, Women in Life Science Norway (Wild Norway)

partneringONE power up workshop

12:00 - 12:30
Relax and Learn

Location: Room K12

Pick up your lunch and join us for this interactive workshop for delegates familiar with partnering who want to up their game. We will cover best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates, and partneringONE power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have. This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can't attend a session, drop by the partnering help desk with any questions.

Participants

Speaker: Jordan Stillman - Project Manager, partneringOne

"Knowing Me, Knowing You": A tête-à-tête on global trends and the next wave of biopharma innovation

13:00 - 13:45
Business of Biotech

Location: Room K1

In this scene setter session, join leading industry advisors Citeline and IQVIA, as they discuss key challenges facing decision makers in research-driven biopharma companies. From R&D through to market access and launch excellence, in key disease areas such as rare diseases, the conversation will touch on the fast-changing dynamics across the entire biopharmaceutical value chain. This data driven fireside chat, filled with relevant case studies, is highly educational and sets the scene for the in-depth panel discussions to follow throughout BIO-Europe.

Participants

Panelist: Daniel Chancellor - VP Thought Leadership, Norstell

Panelist: Isma Hachi - Director, IQVIA

Drug Delivery: Huonslab

13:00 - 13:15
Company Presentations: Exhibit Stage

Location: Exhibit Stage

Huonslab Co., Ltd., a subsidiary of Huons Global Co., Ltd., South Korea (KOSDAQ: 084110), was established in 2018 under the leadership of Huons Group Chairman Sung Tae Yoon. Huonslab is dedicated to advancing biologics research and development with a pioneering spirit. Central to its mission is the development of innovative drug delivery technologies such as HYDIFFUZE™ for universal antibody Sub-Q delivery based on recombinant human hyaluronidase PH20. With a robust pipeline that includes HLB3-002 (currently in pivotal Phase 1, rHuPH20, dispersion agent, BLA aimed in 2026 in Korea) and ongoing non-clinical developments in Alzheimer's, Obesity, and Diabetes, Huonslab exemplifies a commitment to addressing unmet medical needs of patients. Huons Global Co., Ltd., the parent company, is a publicly traded holding company listed on the KOSDAQ since 2006, encompassing 11 subsidiaries specialized in Bio, Pharmaceuticals, and Healthcare. With over 2,200 employees worldwide, Huons Global has demonstrated consistent corporate profitability, achieving a 19-year Compound Annual Growth Rate (CAGR) of 19%. In 2023, Huons Global reported approximately \$583 million in sales revenue, marking a 14% increase from the previous year, and an operating profit of approximately \$88 million, a 33% rise year-over-year.

Participants

Presenter: Young Sun Lee - CBO, Huonslab

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

CNS/Neurology: Tonix Pharmaceuticals Holding Corp.

13:00 - 13:15

Company Presentations: Room K18

Location: K18

Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated by significant improvement on the primary pain endpoint and on all six key secondary endpoints. RESILIENT was the second Phase 3 study to reach statistical significance on the primary endpoint. New Drug Application (NDA) submission to the FDA on track for the second half of 2024.

Participants

Presenter: Seth Lederman - CEO, Tonix Pharmaceuticals Holding Corp.

Technologies and Tools: Menten AI, Inc.

13:00 - 13:15

Company Presentations: Room K12

Location Room K12

Menten AI is developing generative AI to design next-generation cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. Its proprietary platform is capable of designing potent and membrane-permeable macrocycles in a matter of days. The team has shown in vitro and in vivo validation of their platform for complex drug targets including protein-protein interfaces (PPIs) and intracellular targets. The company has partnerships with top-10 pharma to accelerate their preclinical drug discovery efforts. Menten AI is backed by top VCs including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y-Combinator.

Participants

Presenter: Hans Melo - CEO, Menten AI, Inc.

Drug Delivery: DelSiTech Ltd

13:15 - 13:30

Company Presentations: Exhibit Stage

Location: Exhibit Stage

DelSiTech is the leader in using and developing biodegradable, amorphous silica (SiO₂) matrix and sol-gel encapsulation technologies in drug delivery. The applicability of Silica Matrix technology is widespread. Silica matrix technology enables parenteral drug delivery routes such as subcutaneous, intramuscular, intraocular, and topical delivery, among many others. In addition, the therapeutic indications that the company is working on include metabolic diseases, musculoskeletal diseases, infectious diseases, oncology, and pain.

Participants

Presenter: Frederic Dargelas - Senior Director, Head of Business Development and Alliance Management, DelSiTech Ltd

CNS/Neurology: Herantis Pharma Plc

13:15 - 13:30

Company Presentations: Room K18

Location: K18

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease. Herantis' lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. Herantis plan to start a Phase 1b clinical trial in 2H 2024. The primary aim of this clinical trial is to show that repeated subcutaneous doses of HER-096 are safe and well-tolerated in patients with Parkinson's disease. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Participants

Presenter: Antti Vuolanto - CEO, Herantis Pharma Plc

Technologies and Tools: DP Technology

13:15 - 13:30

Company Presentations: Room K12

Location Room K12

DP Technology, established in 2018, is a global pioneer in the "AI for Science" research paradigm. The company is dedicated to solving critical scientific problems by applying advanced Artificial Intelligence and Molecular Simulation algorithms. Our comprehensive computational platform, RiDyMO®, harnesses a deep understanding of physical principles alongside cutting-edge artificial intelligence, unlocking new prospects for structure and dynamics-based drug discovery. DP focuses on three disease areas: autoimmune, neurology and oncology. Currently, we have multiple pipelines under development.

Participants

Presenter: Xiaomin Zhang - Head of Drug Discovery, DP Technology

Drug Delivery: AmacaThera

13:30 - 13:45

Company Presentations: Exhibit Stage

Location: Exhibit Stage

AmacaThera is a clinical stage biopharmaceutical company specializing in the development of advanced sustained release hydrogel formulations to solve key delivery challenges with off patent and proprietary therapeutics. AmacaThera is developing a pipeline of of pain management and oncology assets including AMT-143, a slow release non-opioid local anesthetic for pain. AmacaThera is dedicated to transforming therapeutics to make a difference in patient health.

Participants

Presenter: Darren Rodenhizer - Director, Business Development, AmacaThera

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

CNS/Neurology: Lumosa Therapeutics

13:30 - 13:45

Company Presentations: Room K18

Location: K18

Lumosa Therapeutics is a biotech company dedicated to creating solutions for diseases with urgent unmet medical needs, like stroke. We seek partners to in licensing early stage opportunities in treating neurological diseases. Through Translational research and clinical development, we out-license to partners with global commercial capabilities. Our current pipeline include: LT1001 (Naldebain®) for treating Postoperative pain (Marketed); LT3001: Acute ischemic stroke (Phase 2) and LT6001: CSN/ Exosome (Preclinical). With successful experience to partner and commercialize previous product, we see the potential in LT3001 to fulfill the unmet medical need for treating Acute Ischemic Stroke. In the future, Lumosa aims to expand our pipeline, and become an expert for treating neurological diseases.

Participants

Presenter: Todd Ban - BD Head, Lumosa Therapeutics

Technologies and Tools: Pattern Computer, Inc.

13:30 - 13:45

Company Presentations: Room K12

Location Room K12

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ (PDE) to successfully discover, patent and test seven new drug combinations to treat two of the top cancers, which are now ready for human trials. The Company applies the PDE to the challenging fields of drug discovery, multiomics, biomarkers and diagnostics, increasing accuracy, predictability data results, discovering patterns that companies can capitalize on. • Pattern Discovery Engine™- discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Life Sciences- diagnostics - identifying signatures in 'omics' and focused on combination and repurposed drugs; diagnostic device that is more accurate, uses no reagents, earlier detection, portable, and providing results in 3 seconds with a small sample of saliva, urine or blood- currently working on COVID and more than eight other diseases with our partners, along with projects focusing on toxicity levels and diseases in saliva with the DoD and two national laboratories. Therapeutics – in oncology, as above. • XAI- analytical tools able to reveal the 'how' and 'why' of a system's predictive success – we challenged ourselves to step up from Generative AI and create our PDE to have the ability to tell you how and why of the results. Called “the most advanced ML company on the planet” by the U.S. Department of Energy. • Commercial engagements- include discovering the critical patterns in breast cancer bioindicators in women's tears, allowing partner to bring this product to market; confirming bioindicators in pancreatic cancer detection; improving global prediction rates for colorectal cancer; improving conjunctivitis diagnostics for surgery requirements.

Participants

Presenter: Mark Anderson - Founding Chair & CEO, Pattern Computer, Inc

Drug Discovery and Development: Insilico Medicine

13:45 - 14:00

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Insilico Medicine is a leading generative AI-driven biotech company. Our mission is to accelerate drug discovery and development by leveraging our robust Pharma.AI platform and robotics across biology, chemistry and clinical development. With 31 programs in pipeline including a Phase 2 asset, 6 Phase I assets and multiple pre-clinical stage assets, our generative AI platform helps us advance the pipeline of novel drug candidates rapidly and effectively in oncology, fibrosis, immunology, anemia, and beyond.

Participants

Presenter: Michelle Chen - CBO, Insilico Medicine

CNS/Neurology: STALICLA SA

13:45 - 14:00

Company Presentations: Room K18

Location: K18

Stalicia is a global, clinical-stage biotechnology company focused on advancing precision medicine for brain diseases. Founded in 2017, Stalicia has raised over \$75m in private capital and non dilutive funding. Stalicia's shareholders include Novartis, Pictet, Edmond de Rothschild and SPRIM. Stalicia has developed a unique neuro precision platform, DEPI, with a first application in Autism Spectrum Disorder through the clinical development of 2 precision autism assets: STP1 and STP2. STP1 will be entering Phase 2 this year. Stalicia is also advancing STP7 (mavoglurant) licensed from Novartis, into Phase III clinical trials for substance use disorders in partnership with the National Institute of Health. STP7 offers additional multi-faceted late-stage clinical development opportunities in the wider CNS field. STALICLA is now preparing a 75m-Series C to support STP1 & STP2 phase 2, develop STP7 in additional CNS indications and expend its neuro precision pipeline through the in licensing and development of a new PhII asset for which Stalicia has already secured a \$24m financing option.

Participants

Presenter: Lynn Durham - CEO & Founder, STALICLA SA

Vaccines: nCage Therapeutics

13:45 - 14:00

Company Presentations: Room K12

Location Room K12

Private Biotechnology Company. Limited Liability company under Polish law. Three person management board. Supervisory board comprising investors with governance rights

Participants

Presenter: John Bason - CEO, nCage Therapeutics

"The Name of the Game": Strategic synergies in biopharma dealmaking, M&A trends and alliance management - time for a rethink?

14:00 - 14:45

Business of Biotech

Location: Room K1

As the biopharma industry experiences unprecedented scientific advancements, along with shifting priorities of both pharmaceutical and biotech companies, this session explores whether it is time for a rethink of how strategic synergies are identified and leveraged in biopharma deals, and how they are combined and nurtured once the deal is done. Gain insights into emerging trends, the importance of aligning scientific innovation with commercial potential, actionable strategies to rethink the approach to M&A in a rapidly evolving market, and how to foster an environment of mutual growth and innovation after a deal is signed and, in the years to come.

Participants

Moderator: Ed Saltzman - Senior Strategic Advisor, Humanity

Panelist: Elena Cavalli - Head of Commercial & Enterprise Alliances, Business Development, Astellas Pharma

Panelist: Morten Graugaard Dossing - Partner, Novo Holdings

Panelist: Lubor Gaal - CFO and CBO for Circio Holding and Managing Director, BDLG, Circio AB

Panelist: Philippe Lopes-Fernandes - CBO and Executive VP, IPSEN

Panelist: Tim Opler - Managing Director, Stifel Institutional

Drug Discovery and Development: Origenis GmbH

14:00 - 14:15

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Origenis developed an integrated, largely automated and self-learning technology platform ranging from identification and analysis of innovative targets, design of lead structures/lead structure classes, their pharmacokinetic and metabolic optimization, to patentability searches. A special component of our technology suite and expertise is the ability to specifically design molecules crossing of the blood-brain barrier. After spinning out our LRRK2 inhibitor program in Neuron23, a California-based company, supported by blue chip investors like SoftBank, Westlake, Kleiner Perkins, Perceptive, Cowen Healthcare Investments, Redmile Group, HBM and Surveyor Capital, we focussed on our internal pipeline:

- Our most advanced program – inhibition of CDK9 – is in IND enabling toxicology studies. CDK9 has garnered high interest as one of the central switches in tumor development and progression. Origenis is the only player with a CDK9 program being highly potent, extremely selective and with the ability to efficiently cross the blood-brain barrier, thereby providing inroads also for forms of cancer and viral infections in the brain.

- In our pipeline we are working on selective inhibitors of CDK2, CDK16, CDK3, CDK17 and CDK5. Further CDK's like CDK13, CDK14, CDK4, CDK6 and CDK8 are under consideration. Furthermore we are progressing a NIK inhibitor program, providing - among other indications - a promising approach to target cholangiocarcinoma and certain inflammatory diseases. We pursue a spin off strategy, where assets are transferred in own legal entities, which get staffed and funded separately.

Participants

Presenter: Hendrik Liebers - Chairman, Origenis GmbH

CNS/Neurology: Vesper Bio

14:00 - 14:15

Company Presentations: Room K18

Location: Room K18

Vesper Bio is a private, VC-backed, clinical stage company with world-leading domain expertise in Vps10p domain receptors, developing a rich pipeline of first-in-class small molecule sortilin modulators for a number of critical unmet medical needs within neurodegeneration.

Participants

Presenter: Paul Little - CEO, Vesper Bio

Immunology: Sareum Ltd

14:00 - 14:15

Company Presentations: Room K12

Location: Room K12

Sareum is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has completed Phase 1 clinical development, achieving high blood levels without serious adverse events. Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange.

Participants

Presenter: Tim Mitchell - COO, Sareum Ltd

Drug Discovery and Development: Pioneering Medicines

14:15 - 14:30

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Pioneering Medicines is Flagship Pioneering's in house drug discovery and development unit. Pioneering Medicines was formed to accelerate the creation of novel therapeutics and maximize the value creation and patient impact of Flagship's first-in-category bioplatfroms. We're here to make new medicines for patients, sooner. Our team of drug development experts creates new therapeutics built from Flagship's innovative bioplatfroms and novel modalities. More than 40 companies across the Flagship ecosystem are pioneering innovative platform technologies to address major challenges in human health. Pioneering Medicines explores and identifies new product concepts and then works jointly with Flagship's companies to form integrated teams that advance medicines through robust discovery and early clinical development. Pioneering Medicines also partners with external collaborators across biopharma throughout our R&D process. We apply our unique approach to the R&D priorities of our partners through highly co-creative relationships that draw on the expertise of our respective teams.

Participants

Presenter: Fang Zhang - VP, Business Development, Pioneering Medicines

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

CNS/Neurology: Neuviso

14:15 - 14:30

Company Presentations: Room K18

Location: K18

Neuviso is a private, late-clinical stage biopharmaceutical company dedicated to creating and delivering advanced treatments for ALS and other neurodegenerative diseases. Neuviso has developed a proprietary technology platform that includes a patented macrophage-targeting technology, NP001, and its manufacture. NP001 is designed to address the heterogeneity and progression of ALS by reducing chronic inflammation through the regulation of the innate immune system, a key factor in the loss of motor and respiratory function in ALS, and pathology seen in other neurological diseases. To date, the treatment has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are diligently working to move this compound toward regulatory approval, with the goal of delivering an effective new treatment to reduce the suffering caused by ALS as early as late 2025.

Participants

Presenter: Matthew Davis - CMO, Neuviso

Dermatology: Alphyn Biologics

14:15 - 14:30

Company Presentations: Room K12

Location Room K12

Alphyn is developing breakthrough therapies to treat the most challenging, severe, and common skin diseases. Our Zabalafin (AB-101) Drug Platform contains multiple bioactive compounds that power a new class of therapeutics capable of attacking disease in numerous ways. This unique approach enables the development of Multi-Target Therapeutics™ that target multiple diseases, and multiple symptoms and causes of each disease target. Alphyn's lead drug candidate for atopic dermatitis (AD), Zabalafin hydrogel (AB-101a), completed Phase 2a clinical trials demonstrating strong efficacy against itch, and the inflammatory and bacterial components of AD, with a strong safety, side effect and patient tolerability profile to be the first AD drug for worry-free continuous and long-term use. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates. Alphyn's second therapeutic candidate is for epidermolysis bullosa, a collection of rare and life-threatening skin diseases.

Participants

Presenter: Neal Koller - CEO, Alphyn Biologics

Drug Discovery and Development: Rejuvenate Biomed

14:30 - 14:45

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Rejuvenate Biomed is a clinical-stage biotechnology company developing therapeutics that target the root causes of age-related diseases. Utilizing two clinically validated proprietary drug discovery platforms, the AI-enabled in silico CombinAge™ and in vivo CelegAge™, Rejuvenate Biomed has built a pipeline of five unique combination drugs targeting different age-related diseases, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative indications. Its lead Phase 2-ready asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. The company's disease agnostic drug discovery platforms continue to provide insight into future therapeutics, driving pipeline growth and potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to promoting healthy aging.

Participants

Presenter: Ann Beliën - Founder & CEO, Rejuvenate Biomed

CNS/Neurology: Magdalena Biosciences, Inc.

14:30 - 14:45

Company Presentations: Room K18

Location: Room K18

Filament Health (Filament) and Jaguar Health (Jaguar) joined forces in early 2023 to create Magdalena Biosciences, Inc. in order to leverage their mutual expertise in botanical drug development, plant sourcing and sustainable supply, scientific advisors, neuroscience capabilities, regulatory experience with FDA for botanical drug approval, benefit sharing with indigenous populations, expertise in clinical development, manufacturing, bioassay preparation and performance, and Jaguar's knowledge-based library of plants and extracts. OneSmallPlanet (OSP), who made the seed investment in Magdalena, invests in programs where there is benefit sharing with indigenous populations, including drug development programs. The focus of Magdalena Biosciences, Inc. (Magdalena) is the development of botanical drugs under FDA Botanical Guidance, targeting the initial indications of schizophrenia, attention deficit hyperactivity disorder (ADHD), social anxiety disorder, and depression. In addition, Magdalena has prepared a dossier of safety information from the human experience for the Company's first IND-enabled botanical drug along with the clinical study protocol and drug master file (DMF) and will do so for additional botanical drugs for ADHD, schizophrenia, depression and anxiety, among other neuropsychiatric indications. With pre-IND discussion with FDA, any further in vitro testing or limited toxicology if needed will be performed and Magdalena will be ready to begin clinical studies with Series A funding. Two more botanical drugs will be IND-enabled in 2025. In some cases, the first clinical study will be a Ph 2 study based on centuries of safe use in humans by traditional healers and, sometimes, decades of non-clinical use as a supplement. This process of reaching a POC clinical study within 18 months of program commencement in contrast to the 6 years or more for small molecule drugs, saves time, risk, and money.

Participants

Presenter: Karen Brunke - Acting CEO, Magdalena Biosciences, Inc.

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Dermatology: Azitra Inc.

14:30 - 14:45

Company Presentations: Room K12

Location Room K12

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of *Staphylococcus epidermidis*, or *S. epidermidis*, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit <https://azitrainc.com/>.

Participants

Presenter: Travis Whitfill - COO, Azitra Inc.

Drug Discovery and Development: Veritas In Silico Inc.

14:45 - 15:00

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Veritas In Silico is unveiling the mysteries of RNA and harnessing the potential of messenger RNA (mRNA) as a drug target. Powered by our proprietary in silico technology, we have established an entirely new system for drug discovery that focuses on finding drugs against structural motifs on mRNA.

The discovery of drugs that target mRNA is a promising direction for drug development and a new paradigm for the pharmaceutical industry. It has the potential for application to any disease, including those for which conventional protein-targeted discovery has not yielded effective treatments. Veritas In Silico's mission is to build a warm society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future through the realization of mRNA-targeted drugs.

Participants

Presenter: Ella Morishita - Head of Small Molecule Drug Discovery, Veritas In Silico Inc.

Antibodies: Antengene

14:45 - 15:00

Company Presentations: Room K18

Location: K18

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of cancer and auto-immune diseases patients. Clinical-stage programs: - ATN-022: High-affinity antibody allowing the targeting of Claudin 18.2 ultra-low expressors; in Phase II in AUS and China - ORR 41.7% (including responders with ultra-low CLDN 18.2 expression) - ATN-031: Novel and FIC macrophage activator targeting primarily on solid tumors; in Phase I in the US - ATN-037: Ability in reversing prior anti-PD-1 resistance; consistent efficacy observed in NSCLC and melanoma (ORR 33.3%) pts with acquired resistance from prior anti-PD-1 treatment; to start Phase II in AUS and China - ATN-101: Overcoming liver toxicities of 4-1BB targeting therapies and targeting CPI-relapsed/resistant tumors and "cold" tumors not eligible for CPI-treatment; in Phase I in AUS, US and China Pre-clinical-stage programs: - ATG-042 (MTAPnull-selective PRMT5 Inhibitor): brain-penetrable; in vivo efficacy of ATG-042 is significantly better than that of MRTX171; IND ready by early 2025. - AnTenGager platform (proprietary T-cell engager bispecific platform) + In-house developed proprietary CD3 targeting a unique confirmational epitope of CD3 + "2+1" structure and unique TAA-dependent CD3 binding and activation mitigates risk of cytokine release syndrome and hook effect while enhancing efficacy + Multiple novel bispecific antibodies for oncology indications are under pre-clinical development - ATG-201 (CD19 x CD3 bsAb): targeting for the treatment of autoimmune diseases such as SLE, etc. Preclinical studies demonstrated superior efficacy and reduced risk of cytokine release syndrome compared with BMKs; IND-enabling and CMC work is on-going

Participants

Presenter: Ariel Guo - Chief of staff, Antengene

Biomarkers/Diagnostics/Imaging: COGNANO, Inc

14:45 - 15:00

Company Presentations: Room K12

Location Room K12

Cognano is a venture that aims at computer-aided drug discovery. Utilizing large VHH data obtained from alpacas, we are developing a new drug discovery platform to optimize drug design and development. We are actively seeking development partners for our newly identified cancer-specific antigens and antibody drugs. Our focus areas include:

- Triple-negative breast cancer (TNBC)
- Pancreatic cancer
- Small cell lung carcinoma

Participants

Presenter: Akihiro Imura - CEO and Founder, COGNANO, Inc.

"Do You Know (What It Takes)": Meet the dealmaker - Soeren Moeller, Novo Holdings

15:00 - 15:30

Business of Biotech.

Location: Room K2

Participants

Moderator: Mary Clark - CEO, Optimum Strategic Communications

Panelist: Soeren Moeller - Managing Partner, Novo Holdings

mRNA Innovation for Pandemic Preparedness and Public Health Solutions in LMICs

15:00 - 15:20

Therapeutic Insights

Location: Room K11

The presentation will provide an opinion and information on global trends in RNA innovation with special reference to the scientific challenges of access and affordability for LMICs. It will highlight partnerships and future developments in the RNA space to ensure pandemic preparedness and interpandemic sustainability is achieved in a synergistic model.

Participants

Presenter: Petro Terblanche - CEO, Afrigen Biologics

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Break and breathe

15:00 - 15:15
Relax and Learn

Location: Exhibit Hall Stage

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

Sustainability Focus Area: Social Responsibility

Merck's EMEA Advance Biotech Grant at BIO-Europe

15:20 - 16:40
Therapeutic Insights

Location: Room K11

Through their EMEA Advance Biotech Grant Program, Merck recognize standout emerging biotech companies and helps them navigate their path to commercialization. Delivered as a dynamic competition, five selected biotech companies will have the opportunity to pitch their breakthroughs to Merck's Grant representatives and the overall BIO-Europe audience.

Finalists:

Fuse Vectors

Gene Vector Barcelona, S.L.

GlyProVac LLC

Ikarovec

Theriva Biologics SL

Participants

Moderator : Alexandre Laly - Emerging Biotech Consultant , France & Benelux, Merck

Judge: Inigo De La Fuente - Emerging Biotech Consultant, South, Merck

Judge: Bertram Lutz - Emerging Biotech Consultant, DACH, Merck

Judge: Melissa Nackovski - Emerging Biotech Consultant, Nordics, Merck

Judge: Adam Robertson - Emerging Biotech Consultant, UK & Ireland, Merck

Judge : Sven Verguts - Associate Director, Emerging Biotech & ATMPs, Merck

"Money Money Money": Building a robust venture ecosystem for the next generation of innovations

15:30 - 16:15
Business of Biotech

Location: Room K1

In an era of unprecedented scientific advancements, the life sciences sector is ripe with opportunities for groundbreaking discoveries. However, translating these discoveries into marketready solutions requires a robust and resilient venture ecosystem. This panel session will bring together corporate and financial venture capitalists to discuss strategies for fortifying the European venture landscape, ensuring it is well-equipped to support the next generation of life science breakthroughs.

Participants

Moderator : Melanie Senior - Writer & Analyst, Nature, Evaluate, IN VIVO

Panelist: Lars Gredsted - Senior Principal, Lundbeckfonden

Panelist: Laura Lane - VP Lilly Ventures , European Head, Eli Lilly & Co

Panelist: Karl Naegler - Partner, Sofinnova Partners

Panelist: Marten Steen - Managing Partner, HealthCap

Panelist: Nick Williams - Partner, Medicxi

"Take a Chance on Me": How and why to apply for competitive EU research grants

15:30 - 16:00
Ecosystem Innovation

Location: Exhibit Hall Stage

The Innovative Health Initiative (IHI) is an EU public-private partnership funding health research and innovation. Being part of our large-scale, ambitious projects delivers multiple benefits to participants, including funding, networking, access to knowledge and resources, and new business opportunities. However, applying to be part of a project can be challenging. In this session, companies from our projects will share their tips on how to find a strong consortium and submit a winning proposal. They will also set out more broadly the benefits for their companies of joining collaborative projects. The panellists' advice will be relevant for companies interested in applying for funding from similar research and innovation programmes at both EU and national levels.

Participants

Moderator: Niklas Blomberg - Executive Director, Innovative Health Initiative

Panelist: Kelly Gray - Director, Open Innovation, AstraZeneca

Panelist: Claire Skentelbery - Director General, EuropaBio

Rare and Orphan Diseases: Op2Lysis Development

16:30 - 16:45
Company Presentations: Exhibit Stage

Location: Exhibit Stage

Op2Lysis is a French-Belgian biotech company focused on the development of innovative new treatments for patients with cerebrovascular thrombotic diseases, entering clinical phase early 2025. Looking to raise up to €11M EUR in capital, to complete their €27M EUR Series A round. The proceeds will be used to (i) complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with supra-tentorial hemorrhagic stroke and (ii) develop their pipeline of thrombolytic agents, based on their unique NANOp2Lysis® platform, for indications such as infra-tentorial hemorrhagic stroke and ischemic stroke. • Op2Lysis is offering a breakthrough technology accessible to any hospital in order to reduce patient dependency and associated costs. Development choices are based on an existing documented clinical proof of concept. Op2Lysis researches and develops innovative medicines whose purpose is to lyse hematoma and blood clot formed during thrombosis in the brain. • Op2Lysis is led by an experienced team that combines biopharma, technology, cardiovascular/neuroscience, clinical and project management and business expertise, and backed by a robust BoD and renowned SAB. • Op2Lysis' team has demonstrated the capacity to raise equity capital (€2.8M) and to secure non-dilutive funds from European Innovation Council accelerator, bpifrance and Wallonia funds. • De-risked pharmaceutical (industrial manufacturing process scale-up) and clinical developments (pre-IND meeting already held with the FDA, clinical study design successfully applied previously). • Potential for accelerated/conditional approval as soon as 2028, market exclusivity and favorable pricings in a favorable competitive landscape (unmet medical need for a life-threatening condition for which there is no approved treatment yet) - Orphan Drug Designations already granted by the FDA and the EMA • Sales potential (> €1B peak sales anticipated by 2032)

Participants

Presenter: Christophe Gaudin - CEO, Op2Lysis Development

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Antibodies: IntoCell Inc

16:30 - 16:45

Company Presentations: Room K18

Location: Room K18

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialization of novel antibody drug conjugate platform technologies. The company has developed a state-of-the-art linker technology comprising of a novel self-immolative group based on Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OHPAS linker was designed to accommodate a wide variety of functional groups and triggering groups. The OHPAS Linker can be triggered by methods that include enzymes (i.e. lysosomal), light, and pH. The resulting ADCs have been shown to be highly stable and have very fast payload release profiles. IntoCell has devised another ADC platform technology called Payload Modified Technology (PMT) in which temporary Modifying Group (MG) has been incorporated into traditional payloads. PMT has shown to improve therapeutic index of ADCs with significant reduction of normal cell's uptake, resulting in normal cells being minimally affected. By utilizing PMT and OHPAS linker technology, IntoCell has successfully delivered a preclinical candidate in the B7-H3 ADC program. ITC-6146R0, the lead candidate, shows efficacy in various PDX models and has validated stability in mice, rats and NHPs. The IND Submission is planned for 1Q in 2025. Our have also led to the expansion of the OHPAS linker to Topo 1 inhibitors (Camptothecins), notably Nexatecan. Our Her2 ADC, employing Nexatecan, has demonstrated a broader therapeutic index compared to Enhertu in non-GLP cyno toxicity studies. Nexatecan has consistently outperformed Deruxtecan in vivo, across various comparative studies involving Her2, Trop2, and Her3 targets. We are actively pursuing partners worldwide for the development and commercialization of B7-H3 ADC. Additionally, we welcome opportunities for research and development collaborations with parties keen on exploring our proprietary ADC technologies.

Participants

Presenter: Sung-Ju Moon - CSO, IntoCell Inc

Metabolic Diseases: Abliva AB

16:30 - 16:45

Company Presentations: Room K12

Location: K12

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD^+ and NADH, is currently in a pivotal study with the goal to submit the program for regulatory consideration at the end of 2027. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit www.abliva.com. Subscribe to our news and follow us on LinkedIn and YouTube.

Participants

Presenter: Ellen Donnelly - CEO, Abliva AB

Merck's Partnering Approach

16:40 - 17:00

Therapeutic Insights

Overview of Merck's partnering approach in healthcare

Participants

Presenter: Alan Ginsberg - VP, Head of New Therapeutic Areas Business Development, Merck

Rare and Orphan Diseases: Azafaros

16:45 - 17:00

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Azafaros is a clinical-stage company founded in 2018 by scientists with a deep understanding of rare genetic disease mechanisms, using discoveries made by scientists at Leiden University and Amsterdam UMC. Azafaros is led by a team of highly experienced industry experts and aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. The Azafaros team is dedicated to rapidly bring new drugs to the rare disease patients who need them. The company is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.

Participants

Presenter: Stefano Portolano - CEO, Azafaros

Antibodies: Novelty Nobility Inc.

16:45 - 17:00

Company Presentations: Room K18

Location: Room K18

Novelty Nobility Inc. is a clinical-stage biotech company with locations in Pangyo, South Korea, and Cambridge, U.S. Modest yet bold, we strive to deeply understand what a good, fit-for-purpose antibody is, how it is made, and how we can use it to improve patients' lives. From neutralizing unwanted antigens or blocking a signaling pathway to delivering immune cells or chemical agents to a specific location, antibodies function in various ways. Our mission is to maximize the potential of therapeutic antibodies by leveraging the drug development principles we pursue - novel science led by noble management. Our science-driven imagination and deep-rooted hands-on expertise in protein discovery and translational development enable us to bring our mission to reality. The most mature assets in our antibody-based drug portfolio are centered on c-Kit as a therapeutic target for retinal disease and c-Kit expressing cancers. Through this pipeline-in-an-asset approach, three internally discovered and developed iterations of our anti-c-Kit antibody are in clinical development in the U.S. NN3201, an antibody drug conjugate (ADC) utilizing MMAE as its payload, is on track to initiate a first-in-human Phase 1 trial for patients with c-Kit associated cancers such as SCLC and GIST starting Q3 2024. NN2101, an anti-c-Kit monoclonal antibody (mAb) has been cleared for Phase 1 study in DME patients while a Phase 1 study of SLRN-517 (formerly NN2802) in chronic urticaria patients is ongoing through our licensee, Acelyrin. Further, we have several promising next-generation preclinical assets in our pipeline including NN4101, a bispecific antibody (bsAb) targeting c-Kit and VEGF for retinal diseases, and NN3206, an ADC with an undisclosed novel target for the treatment of pan-RAS cancers.

Participants

Presenter: Arlo McGinn - COO, Novelty Nobility Inc.

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Midsize Pharma: Chugai Pharmaceutical Co., Ltd.

16:45 - 17:00

Company Presentations: Room K12

Location Room K12

Chugai, a member of Roche group, is a Japanese company focused on creating innovative medicinal products which address unmet medical needs. Our innovative antibody technologies have led to multiple therapeutics helping patients around the world. We are the leaders in oncology therapeutics in Japan and have an overall top-level presence in the Japanese pharmaceutical industry.

Our proprietary products, discovered and developed by Chugai, include the anti-IL-6 monoclonal antibody Actemra®/RoActemra® (tocilizumab), ALK inhibitor Alecensa® (alectinib) and anti-FIXa/FX bispecific antibody Hemlibra® (emicizumab), all of which are approved worldwide and illustrate our robust drug R&D capabilities.

Chugai is keen to collaborate with companies with innovative drug discovery technologies. As well, we seek clinical stage licensing opportunities in the oncology, ophthalmology, neuroscience, and immunology areas.

Participants

Presenter: Seiichi Inamura - Head of Search and Evaluation Group, Chugai Pharmaceutical Co., Ltd.

"How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors

17:00 - 18:00

Business of Biotech

Location: Room K1

Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences.

Participants

Moderator: Philip Engell Brainin - Associate, Sound Bioventures

Panelist: Anta Gkelou - Partner, Sofinnova Partners

Panelist: Renee Lucander - CEO, Calliditas Therapeutics

Panelist: Bobby Soni - CIO, BioInnovation Institute

"Beautiful Life": Atossa Therapeutics and the Karolinska Institute: The SMART study: A unique Swedish American collaboration to prevent breast cancer

17:00 - 17:30

Business of Biotech.

Location: Room K2

Interval cancer is a breast cancer diagnosed during the interval between two screening mammograms. Interval breast cancers tend to be larger, grow and spread more quickly, and have a worse prognosis than screening detected breast cancers. Approximately one third of all cancers diagnosed in a screened population are interval cancers.

If women at increased risk of interval breast cancers and effective means to prevent breast cancer could be identified it will have a profound impact on female health given that one woman in eight will be diagnosed with breast cancer. This would be a similar approach as used by cardiologists when identifying and treating individuals with hypertension or high blood lipids to reduce the risk of myocardial infarction and stroke.

The SMART (Stockholm Mammography Risk stratified Trial) will enroll 70,000 healthy women and use a imaging-derived and AI based risk model to identify women with the highest risk of developing breast cancer within the next two years. Approximately 20% of women are considered to be at increased risk and will be offered contrast enhanced mammography and serve as the foundation for a future, Phase 3, trial investigating (Z) endoxifen Atossa's novel SERM (selective estrogen receptor modulator) for prevention of interval breast cancers.

Participants

Moderator: Ed Saltzman - Senior Strategic Advisor, Humanity

Panelist: Per Hall - Professor, Senior consultant, Karolinska Institutet

Panelist: Steven Quay - Chairman of the Board and CEO, Atossa Therapeutics

Rare and Orphan Diseases: PRG S&Tech Inc.

17:00 - 17:15

Company Presentations: Exhibit Stage

Location: Exhibit Stage

PRG S&Tech is a company specializing in the research and development of treatments for rare genetic diseases. Developing non-marketable treatments for such diseases is inherently challenging, especially given the difficult business environment in the pharmaceutical industry. However, we are committed to honoring the dignity and value of every single life. Our mission is to develop the world's first-in-class new drugs for patients suffering from incurable diseases and to become a company that relentlessly pursues the goal of healthy living. We are dedicated to finding effective ways to combat genetic diseases that currently have no cure, driven by our mission: "No one should be left out when it comes to living a healthy life." To achieve this, PRG S&Tech is focused on investigating the causes of rare genetic diseases and developing medicines that target these underlying causes. Our major pipelines under development include treatments for Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS), as well as Amyotrophic Lateral Sclerosis (ALS) and Neurofibromatosis Type 2 (NF2). Furthermore, we aim to discover treatments for neurodegenerative diseases, including those related to aging and dementia, through our research on genetic diseases. As Pioneer of Rare Genopathies via Science and Technology, we strive to lead the way in developing innovative treatments and improving the lives of those affected by these conditions.

Participants

Presenter: Minju Kim - Director, PRG S&Tech Inc.

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Antibodies: Sabiad BV

17:00 - 17:15

Company Presentations: Room K18

Location: Room K18

Sabiad: Pioneering Bacterial Infection Diagnosis and Treatment Sabiad focuses on diagnosing and treating bacterial infections, especially those from surgical procedures like joint replacements. History: Founded in 2022 as a spin-out from the University Medical Center Groningen, Sabiad aims to revolutionize infection detection and treatment, particularly in post-operative care. Early Development: Sabiad's founders combined expertise in medical microbiology, orthopedics, business, product development, and regulatory affairs to develop StaphMark, addressing gaps in early infection detection and treatment. Pioneering Research: Sabiad discovered the 1D9 antibody with high specificity for *Staphylococcus aureus*, integrating tracer technology for precise infection imaging. They also developed antimicrobial photodynamic therapy (aPDT) with 1D9-700DX targeting MRSA effectively. Patents and Recognition: Sabiad secured patents EP3080160, US9,944,694 B2, and PCT/NL2014/050857 in the USA and Europe, validating their technology's potential. Growth and Expansion: With substantial funding from grants and venture capital, Sabiad expanded its research, forming key partnerships for preclinical studies and clinical trials. Looking to the Future: Sabiad is poised to impact patient care and the fight against antibiotic resistance, with a roadmap for introducing StaphMark to the market. Healthcare Challenge: Post-operative infections, particularly from MRSA, are challenging to treat due to biofilm formation on implants, making infections difficult to diagnose and eradicate. Differentiating infection from inflammation is also complex, complicating diagnosis and treatment. Sabiad's Solution: StaphMark, centered around the 1D9 antibody, represents a paradigm shift in detecting and treating *S. aureus* infections, improving post-operative care.

Participants

Presenter: Ton van den Hoven - Founder & product management, Sabiad BV

Cell and Gene Therapies: Eutilex Co., Ltd

17:00 - 17:15

Company Presentations: Room K12

Location: K12

Eutilex Co., Ltd. is a South Korean biotech company specializing in the development of innovative cancer immunotherapies, with a focus on T-cell therapies. Founded in 2015, Eutilex aims to harness the immune system to eliminate cancer through T-cell-based technologies and immune checkpoint inhibitors. Core Technologies Eutilex's core technology involves engineering T-cells to more effectively recognize and attack cancer cells. Their T-cell and CAR-T cell therapies offer a powerful and precise treatment option by enabling T-cells to bind to and activate against antigens present on cancer cells. Additionally, Eutilex is developing immune checkpoint inhibitors and immune activators to "release the brakes" on the immune system, allowing for a more effective attack on cancer cells. Key Pipeline EU307 [Phase 1 in Korea]: A fourth-generation CAR-T therapy targeting GPC3, which is highly expressed in liver cancer, and co-expressing the immune-activating cytokine IL18. EU103 [Phase 1 in Korea]: An antibody therapy that blocks the function of M2 macrophages while converting them to M1 macrophages, thereby enhancing the body's immune response against cancer. EU101 [Phase 1/2 in Korea/US, Phase 1 in China]: An antibody therapy targeting the well-known T-cell co-stimulatory receptor 4-1BB, enhancing T-cell cytotoxicity, immune memory, and survival capabilities. EU204 [Phase 1/2a in Korea]: An EBV-positive T-cell therapy targeting NK/T-cell lymphoma, utilizing 4-1BB-based cancer antigen-specific T-cell isolation technology. In addition to these, Eutilex possesses core technologies and research capabilities for the prevention and treatment of zoonotic diseases. Beyond drug development, the company also engages in biosolution businesses, including non-clinical contract research organization (CRO) services and operations through GMP facilities.

Participants

Presenter: Chongsoo Lee - Managing Director, Eutilex Co., Ltd.

Rare and Orphan Diseases: Oncopeptides

17:15 - 17:30

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

While cancer knows no bounds, neither does the power of human resilience and scientific innovation.

Oncopeptides' vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

We are science driven, entrepreneurial, and committed to bringing innovation to patients with diseases where there is a clear unmet need.

Oncopeptides' first drug Pepaxti has been granted full approval for treatment of adult patients with multiple myeloma in Europe.

Our first innovative drug is based on the Peptide Drug Conjugate (PDC) platform, and offers patients robust efficacy, reduces treatment burden and maintains quality of life.

Our pipeline includes other drug candidates built on the PDC platform as well as the Small Polypeptide based Killer Engagers (SPiKE) platform.

We have a values-driven culture and inclusive organization that welcomes people with diverse backgrounds and perspectives.

We are headquartered in Stockholm, Sweden, have 75 coworkers and a modern pre-clinical drug development facility in Solna, outside of Stockholm.

Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

Participants

Presenter: Sofia Heigis - CEO, Oncopeptides

SESSIONS

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Antibodies: Biomissile Pharmaceuticals

17:15 - 17:30

Company Presentations: Room K18

Location: Room K18

Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDAB) and multi-specific antibody (UDAB-M) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDAB) and multi-specific antibody (UDAB-M), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (UDAB) and multi-specific UDAB-M molecules to specifically activate immune cells in the tumor microenvironment (TME) to treat solid tumors, including TAA-low and ADC-resistant. Presently, two leading projects are in clinical stages (Phase I & II) and the third one is in IND filing stage.

Participants

Presenter: Chao Tu - Co-founder, President & CEO, Biomissile Pharmaceuticals

Cell and Gene Therapies: Kolon Life Science, Inc.

17:15 - 17:30

Company Presentations: Room K12

Location Room K12

Kolon Life Science (listed on KOSDAQ), a subsidiary of Kolon Group, is a South Korean biotech company established in 2000. One of its main business areas includes novel biopharmaceuticals, specializing in cell and gene therapies.

There are three gene therapy drug candidates: TG-C for osteoarthritis(US Ph 3 ongoing), KLS-2031 for neuropathic pain (US Ph 1/2a completed), and KLS-3021 as oncolytic virus.

We are currently seeking partners for business development, collaborative research and co-development of our drug assets.

Participants

Presenter: Jungjong Cho - Vice President, Kolon Life Science, Inc.

The Long Game of Trust: How Novo Nordisk Does Partnering

17:30 - 18:00

Business of Biotech.

Location: Exhibit Hall Stage

Join Tomas Landh of Novo Nordisk for an insightful fireside chat on the true nature of biotech partnerships. Tomas will explore how trust and personal relationships are part of the foundational pillars towards success, sharing what makes him choose one partner over another. Learn why a strong, enduring connection takes years to build and why it's crucial in standing out from the crowd. This conversation reflects the 30-year journey of forging meaningful, lasting industry alliances.

Participants

Moderator: Tim Opler - Managing Director, Stifel Institutional

Panelist: Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation, Novo Nordisk

Exhibit Hall Reception

18:00 - 21:00

Location: Exhibit Hall

Time: 18:00 – 21:00

Join us on the busy exhibit floor and wrap up your first conference day with some networking. Catering will feature a variety of smaller, authentic Scandinavian dishes, as well as wines, beer, soft drinks and juices.

In addition, the select exhibitors listed below will be hosting special receptions at their booths, offering a unique opportunity to mingle and enjoy their treats.

Fancy some games and entertainment, or want to relax a bit?

- There will be a karaoke session at the exhibit hall stage from 18:30 until 20:30.
- There will be live music by local artist Karolina Karner & Friends.
- Fun games and soothing massages will be available [at our lounges](#)

Exhibitors:

- Booth 18 - Bayer
- Booth 37 - AlphaSense
- Booth 38 - Biopartner UK
- Booth 49 - Praque.bio
- Booth 53 - Swiss Biotech Pavilion
- Booth 59 - Evotec
- Booth 84 - Citeline
- Booth 85 - Johnson & Johnson Innovation
- Booth 86 - Health~Holland
- Booth 94 - Swedish Pavilion
- Booth 96 - Belgium – Wallonia Export & Investment Agency
- Booth 96 - Flanders.bio
- Booth 96 - Flanders Investment & Trade
- Booth 96 - Belgian Beer
- Booth 97 - LISA Life Science Austria
- Booth 98 - Invest in Canada
- Booth 112 - Schott Pharma
- Booth 157 - Catalent
- Booth 162 - Biosaxony
- Booth 165 - Dentons

SCHEDULE

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	RELAX AND LEARN.	RELAX AND LEARN	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: EXHIBIT STAGE	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12
06:00	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session	06:30 - Biotech-Bikers Spin Session
07:00	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)
08:00	08:30 - Buzz Session: Winning Presentations, Influencing Partnerships 08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)
09:00		09:30 - partneringONE essentials workshop								

SCHEDULE

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	RELAX AND LEARN.	RELAX AND LEARN	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC IN-SIGHTS	ECOSYSTEM IN-NOVATION	COMPANY PRE-SENTATIONS: EX-HIBIT STAGE	COMPANY PRE-SENTATIONS: ROOM K18	COMPANY PRE-SENTATIONS: ROOM K12
10:00			10:00 - "The Way Old Friends Do": Opening remarks 10:30 - "Super Trouper": The entrepreneurial magic							
11:00			11:00 - "Voulez-Vous?": Investing in a sustainable future with global pharma							
12:00		12:00 - partneringONE power up workshop		12:00 - Lunch			12:00 - "Listen to Your Heart": Navigating the wild path - Nordic leaders raising the ceiling for women			

SCHEDULE

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	RELAX AND LEARN.	RELAX AND LEARN	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC IN-SIGHTS	ECOSYSTEM IN-NOVATION	COMPANY PRE-SENTATIONS: EX-HIBIT STAGE	COMPANY PRE-SENTATIONS: ROOM K18	COMPANY PRE-SENTATIONS: ROOM K12
13:00			13:00 - "Knowing Me, Knowing You": A tête-à-tête on global trends and the next wave of bio-pharma innovation					13:00 - Drug Delivery: Huonslab 13:15 - Drug Delivery: DeSiTech Ltd 13:30 - Drug Delivery: AmacaThera 13:45 - Drug Discovery and Development: Insilico Medicine	13:00 - CNS/Neurology: Tonix Pharmaceuticals Holding Corp. 13:15 - CNS/Neurology: Herantis Pharma Plc 13:30 - CNS/Neurology: Lumosa Therapeutics 13:45 - CNS/Neurology: STAL-ICLA SA	13:00 - Technologies and Tools: Menten AI, Inc. 13:15 - Technologies and Tools: DP Technology 13:30 - Technologies and Tools: Pattern Computer, Inc. 13:45 - Vaccines: nCage Therapeutics

SCHEDULE

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	RELAX AND LEARN.	RELAX AND LEARN	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: EXHIBIT STAGE	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12
14:00			14:00 - "The Name of the Game": Strategic synergies in biopharma deal-making, M&A trends and alliance management - time for a rethink?					14:00 - Drug Discovery and Development: Originis GmbH 14:15 - Drug Discovery and Development: Pioneering Medicines 14:30 - Drug Discovery and Development: Rejuvenate Biomed 14:45 - Drug Discovery and Development: Veritas In Silico Inc.	14:00 - CNS/Neurology: Vesper Bio 14:15 - CNS/Neurology: Neuvivo 14:30 - CNS/Neurology: Magdalena Biosciences, Inc. 14:45 - Antibodies: Antengene	14:00 - Immunology: Sareum Ltd 14:15 - Dermatology: Alphyn Biologics 14:30 - Dermatology: Azitra Inc. 14:45 - Biomarkers/Diagnostics/Imaging: COGNANO, Inc
15:00		15:00 - Break and breathe	15:30 - "Money Money Money": Building a robust venture ecosystem for the next generation of innovations		15:00 - "Do You Know (What It Takes)": Meet the dealmaker - Soeren Moeller, Novo Holdings	15:00 - mRNA Innovation for Pandemic Preparedness and Public Health Solutions in LMICs 15:20 - Merck's EMEA Advance Biotech Grant at BIO-Europe	15:30 - "Take a Chance on Me": How and why to apply for competitive EU research grants			

SCHEDULE

DAY 1 - 04/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	RELAX AND LEARN.	RELAX AND LEARN	BUSINESS OF BIOTECH	LUNCH	BUSINESS OF BIOTECH.	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: EXHIBIT STAGE	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12
16:00						16:40 - Merck's Partnering Approach		16:30 - Rare and Orphan Diseases: Op2Lysis Development 16:45 - Rare and Orphan Diseases: Azafaros	16:30 - Antibodies: IntoCell Inc 16:45 - Antibodies: Novelty Nobility Inc.	16:30 - Metabolic Diseases: Abli-va AB 16:45 - Midsize Pharma: Chugai Pharmaceutical Co., Ltd.
17:00			17:00 - "How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors		17:00 - "Beautiful Life": Atossa Therapeutics and the Karolinska Institute: The SMART study: A unique Swedish American collaboration to prevent breast cancer 17:30 - The Long Game of Trust: How Novo Nordisk Does Partnering			17:00 - Rare and Orphan Diseases: PRG S&Tech Inc. 17:15 - Rare and Orphan Diseases: Oncopeptides	17:00 - Antibodies: Sabiad BV 17:15 - Antibodies: Biomissile Pharmaceuticals	17:00 - Cell and Gene Therapies: Eutilex Co., Ltd 17:15 - Cell and Gene Therapies: Kolon Life Science, Inc.
18:00	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Rise & Run

06:30 - 07:30

Led by a local trainer, you will enjoy the light sightseeing through the streets of Stockholm.

WHERE:

Route 1: Stockholm city centre
Meeting point: Lobby of the Scandic Continental Hotel
Vasagatan 22, 111 20

Route 2: Stockholmsmässan
Meeting point at the main entrance of
Stockholmsmässan
Mässvägen 1, 125 30

DURATION: 60 minutes, 6:30 – 7:30

Registration in advance is encouraged! [SIGN UP HERE](#)

Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)

07:45 - 08:45

Location: **Stockholmsmässan**

Light Breakfast: **served until 10:45**

Partnering: one-to-one meetings (8:00 - 18:30 CET)

08:45 - 09:00

One-to-one meetings at BIO-Europe will be scheduled during the hours below:

Meetings on this day will start at **8:00 – 18:30 CET**.

"Keep This Fire Burning": Innovate or acquire? Strategic choices for filling pharma pipelines

09:00 - 09:45

Therapeutic Insights

Location: Room K2

As the pharma patent cliff approaches, this panel will explore its impact on the industry, examining future pipelines and emerging partnering opportunities. Join industry leaders to discuss strategies for innovation and collaboration, ensuring sustained growth and advancement in the life science landscape. Discover what lies ahead in this pivotal decade.

Participants

Moderator: Natasha Choukhar - Senior Manager, Portfolio Advisory Strategy Consulting, Evaluate

Panelist: Fabrizio Conicella - VP - Center of Open Innovation & Competence, Chiesi Group

Panelist: Tanay Ghosh - Deputy Head of M&A Transactions, Novartis

Panelist: Friedemann Janus - SVP, Head of Regional Business Development & Licensing, Co.Lab and Divestitures, Bayer

Panelist: David Jenkins - SVP, Research and External Innovation, Ipsen

Panelist: Prabhu Velusami - Senior Director of Early Innovation Partnering, Johnson & Johnson Innovation

"Live and Learn": Navigating biotech's clinical development challenges: Diverse strategies for thriving in 2024's complex landscape

09:00 - 09:45

Ecosystem Innovation

Location: Exhibit Hall Stage

The biotech industry has faced a 60% reduction in clinical trial initiations in 2024 compared to previous years. Despite some recovery, R&D funding is still below 2020/21 levels, and the complexity and costs of R&D continue to rise. Join this session to gain evidence-based insights and hear from leading women in biotech as they:

- Comment on the current macro environmental challenges impacting clinical development
- Discuss innovative strategies to overcome these hurdles
- Share their perspective on how EU biotech organizations can thrive amidst these challenges

Participants

Moderator: Emma Chaffin - Senior client partner, IQVIA

Panelist: Anta Gkelou - Partner, Sofinnova Partners

Panelist: Jennifer Schneider - CEO, Centauri Therapeutics

Panelist: Aneta Sottit - Partner, Andera Partners

Oncology: Tempus AI, Inc.

09:00 - 09:15

Company Presentations: Room K18

Location: K18

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Participants

Presenter: Shyam Khatau - VP, Life Sciences, Tempus AI, Inc.

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Immuno-Oncology: HanchorBio Inc.

09:00 - 09:15

Company Presentations: Room K12

Location: K12

Founded in December 2020, HanchorBio is a clinical-stage biotech company with footprint spanning across multiple regions (USA, CHN, TWN). We specialize in developing novel, multi-targeting biomedicines through our "Fc-Based Designer Biologics" (FBDB) and "Shielded Designer ImmunoCytokine" (SDIC) platforms. Using proprietary protein engineering techniques, we have obtained an innate immunity engager (HCB101) that exhibits superior in vivo efficacy and marked safety profiles. These were fully demonstrated through in vivo efficacy testing of over 20 cancer models and two monkey toxicology studies. HCB101 is currently going through Phase I clinical trials. Our SDIC cytokine platform represents the most advanced version of guided immunocytokines that comprise all the desirable attributes such as superior safety features, outstanding in-vivo efficacy, favorable thermostability, and extended serum half-life. We have multiple SDIC programs in progress concurrently, covering indications in oncology and autoimmune diseases. As a spin-off from Henlius, HanchorBio's colleagues possess a wide range of expertise and have over 10 years of experience in discovery research. We also recruit excellent scientists worldwide to achieve more diverse capabilities of innovation. This includes operations of an in-house animal facility with over 100 cancer models for in vivo testing. In addition, we have established process development (PD) capability to manage various aspects of upstream, downstream, analytical method developments, and up to 50L GLP toxicology material preparation. Due to this highly efficient, streamlined operation, we are able to advance pipeline programs in a rapid pace, obtaining our first IND clearance from the US FDA in 2.3 years since the company's inception. Our ultimate goal is to overcome the limitations of the current checkpoint inhibitor approaches and lead the immune-based therapies into a new dimension.

Participants

Presenter: Zong Sean Juo - President & CSO, HanchorBio Inc.

Oncology: Spirea

09:15 - 09:30

Company Presentations: Room K18

Location: K18

Spirea is a Cambridge University spin-out advancing a pipeline of Antibody Drug Conjugates (ADCs) with a lead programme targeting a tumour marker over-expressed in a number of cancers including triple-negative breast cancer. Spirea's ADCs incorporate a proprietary linker-payload technology which enables the incorporation of diverse drug payloads at drug-to-antibody ratios > 16. This provides for extremely high ADC design and payload flexibility and wide therapeutic index in cancer/oncology. Spirea is interested in collaborating with biotech and pharma companies to incorporate its high drug loading Antibody Drug Conjugate linker technology into new or pre-existing drug programmes.

Participants

Presenter: Adam Collier - CBO, Spirea

Immuno-Oncology: Txinno Bioscience Inc.

09:15 - 09:30

Company Presentations: Room K12

Location: K12

Txinno Bioscience Inc. established in September 2020 with a vision to give hope and happiness to cancer patients and their family. Main Business Area is a dedicated company developing novel small molecule drugs for targeted therapy and immunotherapy to treat cancer patients. Txinno Bioscience is exclusively focused on developing innovative, small molecule anti-cancer drug candidates. We have 6 assets of various stages, among those, ENPP1 and ULK1 inhibitor are our representative pipelines. Txinno Bioscience is developing anti-cancer treatments focused on two intertwined aspects of physiology of tumor tissue. The first one is defined as tumor-intrinsic factors which are either genes or signaling pathways of tumor cells to directly control tumor cell proliferation or survival. Corresponding assets are ULK1 inhibitor, 'Target S' inhibitor, 'Target I' inhibitor and 'Target Y' inhibitor related to RAS signaling pathway. The other one is defined as tumor-extrinsic factors which are various signaling pathways operating in stromal cells other than tumor cells and promoting cancer cells to survive. Corresponding assets are ENPP1 inhibitor and 'Target Z' inhibitor controlling STING signaling pathway. In Txinno Bioscience, we developed two platform technologies to address these issues and facilitate our drug development process. 1) TxLFinder™ that can cultivate cancer cell spheroid and immune cells from PBMC in separate compartments of microplate wells. With immune cells appropriately stained for detection, the effect of drug treatment on infiltration of immune cells toward the spheroid can be measured. 2) TxTQuantifier™ is a co-culture system that are composed of spheroid from cancer cell line, isolated human immune cells, cancer-associated fibroblast, adipocytes and fabricated extracellular matrix to closely mimic actual human TME.

Participants

Presenter: Sean Ham - BD Team Lead, Txinno Bioscience Inc.

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"Dressed for Success": Evolution of leadership over 30 years

09:30 - 10:15

Business of Biotech

Location: Room K1

Over the past 30 years, there have been profound changes in life science leadership, driven by factors such as advancing technology and more. This session explores the first-hand experience of the journey, from 'scientific expertise' driven leadership to the rise in need for versatile, resilient and forward-thinking leaders, capable of integrating science with business strategy and adapting to rapid technological advancements, to drive innovation in today's increasingly complex and interconnected industry.

Participants

Moderator: Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

Panelist: Edwin Moses - Independent Director and Chairman of the Board, Achilles Therapeutics, Avantium NV and LabGenius

Panelist: Denise Scots-Knight - CEO, Mereo BioPharma

Panelist: John Haurum - Chairman of the Board of Directors and Non-executive Director, CatalYm, Adcendo, Agomab, Neophore, Solid Therapeutics, Storm and SynKlino

Oncology: Etnova Therapeutics Corp.

09:30 - 09:45

Company Presentations: Room K18

Location: K18

Etnova Therapeutics Corp. has been conducting research and development on synthetic drug-based anticancer therapies since its founding in 2022. The company currently consists of 13 members, including 3 PhD-level researchers and 7 Master's-level researchers. All researchers in the company are equipped with the expertise to handle the entire drug discovery process, from identifying new drug libraries, synthesis development, and efficacy evaluation to mechanism of action studies. Guided by the slogan 'A new era of therapeutic advances,' all members are united in striving towards the same goal. Here are the major events in the company's history: • August 2020: Company founded • October 2020: Secured angel investment • March 2022: Secured Series A investment • August 2023: IND approval for Phase 1 clinical trial of major pipeline ETN101 in Korea MFDS • February 2024: First patient enrolled in Phase 1 clinical trial of ETN101 in Korea The key pipeline under development is an oral anticancer drug, ETN101. In August 2023, it received IND approval for Phase 1 clinical trials in Korea, and the trials are now ongoing at four institutions nationwide. As of August 2024, Cohort 3 of the trial is currently in progress. In relation to the above, various indications are being expanded, and 8 national grant projects have been completed or are currently being carried out. As for intellectual property rights, 13 patents have been applied for and registered both domestically and internationally. Etnova Therapeutics completed the Series A investment in 2022 and Bridge investment in 2024, with plans for Series B in 2025. Additionally, we are considering SI/FI investment or licensing out for partnering opportunities. By expanding our pipeline and business internationally, we are strengthening our research capabilities and developing additional platform technologies. Etnova Therapeutics will usher in a new era of therapeutic development with a powerful leap forward.

Participants

Presenter: Garam Choi - Senior Reseracher, Etnova Therapeutics Corp.

Immuno-Oncology: Myeloid Therapeutics

09:30 - 09:45

Company Presentations: Room K12

Location: K12

Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.

Participants

Presenter: Daniel Getts - CEO, Myeloid Therapeutics

Oncology: Tenboron Oy

09:45 - 10:00

Company Presentations: Room K18

Location: K18

Tenboron is a clinical stage biopharmaceutical company developing superior boron carriers for Boron Neutron Capture Therapy (BNCT) of cancers. BNCT is biochemically targeted radiation therapy especially suitable for treatment of non-resectable or recurrent tumors in the head and neck region. BNCT relies on efficient delivery of boron-10 atoms to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells. BNCT has many advantages over conventional radiotherapy, but the adoption of this treatment modality has been handicapped by suboptimal carriers and lack of neutron sources. This is now changing as the construction of several new accelerator-based neutron sources is ongoing globally.

Participants

Presenter: Juha Jouhki - CEO, Tenboron Oy

Immuno-Oncology: Accession Therapeutics

09:45 - 10:00

Company Presentations: Room K12

Location: K12

Accession Therapeutics is developing a proprietary pipeline of highly targeted immuno-oncology products with a range of therapeutic payloads. The ideal immunotherapy is highly specific to a tumour, broad in action to kill all cancer cell variants, and potent in activating the full immune system arsenal locally.

Participants

Presenter: Stephanie Bewick - CBO, Accession Therapeutics

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"Rise and Shine" - Immunology: The next surge on the horizon?

10:00 - 10:30

Therapeutic Insights

Location: Room K2

In an era of rapid scientific progression, Immunology has advanced to be the second-largest segment in the biopharma industry, by sales. Join this session to discover the current state of the field, key drivers behind the growth and delve into significant deals, such as the Morpich and DICE by Eli Lilly. Explore the evolving landscape of licensing and partnering opportunities for novel immunological innovations, and gain insights into emerging trends and prospects in the future.

Participants

Moderator: Begona Carreno - Chief Business Development Officer, Vecturaferitin Pharma

Panelist: David Shrom - AVP External Innovation, Eli Lilly & Company

Navigating the biopharma services landscape: Current trends and future perspectives

10:00 - 10:30

Ecosystem Innovation

Location: Exhibit Hall Stage

We look at how global events, deal making, and regulatory and tech advancements are determining the factors driving or squeezing production, while also finding time to focus on developments within a key area of the industry.

Participants

Moderator : Cormac Sheridan - Journalist, Freelance

Panelist: Benedikt von Braunmuhl - CEO, Rentschler Biopharma

Oncology: Osmol Therapeutics, Inc.

10:00 - 10:15

Company Presentations: Room K18

Location: K18

Osmol is a clinical stage biopharma company developing a first-in-class preventative treatment for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with microtubule-based chemotherapies such as taxanes, the most widely used breast cancer chemotherapy treatment. CIPN can be both debilitating and effect cancer treatment outcomes. There are no approved treatments for CIPN, leaving patients' only option to reduce the dose or length of chemotherapy treatment. Osmol's initial focus is in breast cancer where up to 80% of taxane treated patients develop CIPN and 50% have their dose or length of treatment adjusted. , CIPN is driven by the dysregulation of neuronal calcium sensor-1 (NCS1). Osmol is developing a first-in-class, patented drug (OSM-0205) to modulate NCS1 function to prevent neuronal damage caused by the off-target effects of chemotherapy. The FDA completed its review of Osmol's IND, notifying Osmol that our Phase 1 clinical study may proceed. In vivo and in vitro data support the development and effectiveness of OSM-0205 including: characterization of mechanism of efficacy, validation in mouse models of CIPN, and in vivo demonstration of no effect on chemotherapy efficacy. In addition, a limited clinical experience supports the therapeutic hypothesis. Finally, in vivo data support the potential for efficacy in a follow-on indication, chemotherapy-induced cognitive impairment (CICI). Market research with breast cancer specialists at leading US cancer centers confirmed the significant need for effective CIPN treatment, to prevent CIPN and allow for optimal chemotherapy treatment. In this same market research, payers covering 100M lives in the US confirmed the need for a preventative treatment and would reimburse it. Based on this market research, OSM-0205 peak sales for taxane-treated patients alone is projected to exceed \$1.2B.

Participants

Presenter: Bob Linke - President & CEO, Osmol Therapeutics, Inc.

Immuno-Oncology: VacV Biotherapeutics Limited

10:00 - 10:15

Company Presentations: Room K12

Location: Room K12

VacV is a cancer immunotherapy company developing viral-based therapies for cancer. Our versatile technology uses a novel oncolytic Vaccinia virus and is designed to create efficacious and safe treatments. Our promising pipeline of easy-to-administer treatments includes features that offer significant advantages compared to existing treatment options.

Participants

Presenter: Glyn Edwards - Chairman, VacV Biotherapeutics Limited

"Celebration" Turning the tables: 40 years of industry insight – Mike Ward, the interviewer, becomes the interviewee!

10:15 - 10:45

Business of Biotech

Location: Room K1

Join this session to celebrate 40 years of Mike Ward's remarkable journey in reporting and analyzing the biotech industry. Over four decades, Mike has contributed to publications including Nature, Financial Times, Scrip and more, and has engaged with countless leaders in the pharma, biotech, and investment communities. As his passion and dedication to understanding and communicating the transformative power of biotech remains strong, hear about his experiences, visions for the industry, his future endeavours in the years to come.

Participants

Moderator : Mary Clark - CEO, Optimum Strategic Communications

Panelist: Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

Pharma company presentation: Novartis AG

10:30 - 10:45

Therapeutic Insights

Location: Room K2

Reimagining medicine, together. Working together, we can reimagine medicine to improve and extend people's lives.

Participants

Presenter: Markus Werner - Head Search & Evaluation Oncology, Novartis AG

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"Always Have, Always Will": Creating value by excellence in CMC development

10:30 - 11:00

Ecosystem Innovation

Location: Room K11

From the get-go, start-up and pre-clinical stage biopharmaceutical companies rightfully prioritize the scientific foundation of their invention, then swiftly transitioning towards Clinical Development. The priority is often reserved for securing fast-track, accelerated development pathways and expediting entry into first-in-human studies. Undoubtedly, Clinical Development stands as the key in the drug Information Classification: General development journey, commanding utmost attention: it is the highest risk, highest value creation, highest cost, most challenging, and highly regulated and monitored by Regulators Agencies. However, this pursuit of clinical milestones frequently results in the oversight of Chemistry, Manufacturing, and Controls (CMC) Development. Such neglect stems from underestimating the scope, complexity, timelines, cost, and impact of CMC Development - a prerequisite and indispensable precursor to any Toxicology and Clinical Development. This presentation will cover how to fully integrate CMC Development into the product development lifecycle and how pursuing excellence in CMC development will allow start-up and pre-clinical stage biopharmaceutical companies to realize substantial value.

Participants

Moderator: Christelle Dagonneau - VP, Head of Business Development - Product Development Solutions, ProductLife Group

Panelist: Matthieu Coutet - Partner, Sofinnova Partners

Panelist: Rupert Haynes - CEO, Avata Biosciences

Panelist: Johannes Roebbers - Head of Biopharma Product Development BU at PLG & Managing director at Cilatus group, ProductLife Group

Panelist: Corinne Venot - VP, Business Development, BeiGene

Panelist: Christoph Winterhalter - CBO, AGC Biologics

Break and breathe

10:30 - 10:45

Relax and Learn

Location: Exhibit Hall Stage

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

Sustainability Focus Area: Social Responsibility

Pharma company presentation: Sanofi

10:45 - 11:00

Therapeutic Insights

Location: Room K2

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world's poorest countries

Participants

Presenter: Cedric Barriere - Senior Director Search & Evaluation, Immunology, Sanofi

"Sayit": The Flot.bio show at BIO-Europe: In conversation with Lovisa Afzelius, Flagship Pioneering

11:00 - 12:00

Business of Biotech

Location: Room K1

Join this session to watch an exclusive recording of the Flot.bio Show, filmed for the first time at an event in collaboration with EBD. Host Philip Hemme chats with Lovisa Afzelius, General Partner at Flagship Pioneering. They will talk about the four biotech companies Lovisa co-founded since joining Flagship in early 2020, Flagship's European initiatives, and her journey as one of Sweden's leading female biopharma executives.

Participants

Moderator: Philip Hemme - Founder & CEO, Flot.bio

Panelist: Lovisa Afzelius - General Partner, Flagship Pioneering

Pharma company presentation: MSD

11:00 - 11:15

Therapeutic Insights

Location: Room K2

We aspire to be the premier research-intensive biopharmaceutical company. We're at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

Participants

Presenter: Richard Taylor - Exec. Dir., Business Development & Licensing, European Transactions, MSD

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"A Thing About You": The ecosystem is the product: Unlocking Canada's life sciences advantages in AI and regenerative medicine

11:00 - 11:30
Ecosystem Innovation

Location: Exhibit Hall Stage

Join Dr. Michael May, a visionary leader in regenerative medicine, as he explores the vibrant landscape of Canada's life sciences ecosystem with a special focus on AI and regenerative medicine. This session will showcase Canada's cutting-edge advancements in cell and gene therapy, powered by its world-renowned AI capabilities and collaborative research and innovation culture.

Dr. May will highlight the pivotal role that CCRM plays in advancing regenerative medicine and catalyzing investment in breakthrough therapies. He will also discuss how AI is revolutionizing drug discovery, diagnostics, and personalized medicine in Canada. Attendees will hear first-hand how Canada's research institutions, biotech companies, and innovators are collaborating to deliver life-changing therapies and positioning Canada as a global leader in life sciences.

Highlights:

- Gain insights into Canada's latest innovations in advanced therapy and how they are reshaping healthcare.
- Learn about Canada's thriving life sciences ecosystem and its unique ability to integrate world-class research, government support, and private-sector collaboration.
- Explore investment opportunities in Canada, including access to cutting-edge technologies, talent, and favorable incentives for businesses looking to expand or invest in the country.
- Hear success stories from companies and investors who have leveraged Canada's resources to accelerate their growth in the life sciences industry.

This session is a must-attend for companies, investors, and innovators seeking to understand Canada's competitive edge in life sciences and how they can capitalize on emerging opportunities in AI and regenerative medicine.

Participants

Panelist: Michael May - President & CEO, CCRM

Pharma company presentation: Eli Lilly & Company

11:15 - 11:30
Therapeutic Insights

Location: Room K2

At Lilly, we take smart risks on bold science to achieve our mission of bringing life-changing medicines to patients. As a community of scientists, we understand the brilliance and dedication this work takes. We also recognize our responsibility as partners to help advance life-changing medicines within our walls and beyond. More than 100 years ago, we pioneered strategic collaborations to scale the bold work of four University of Toronto research scientists to launch the world's first commercial insulin. We're proud to continue our legacy in collaboration, with ~50% of our new product launches in the last 10 years enabled by external innovation, and over 70 active alliances with the vibrant academic and biotech ecosystem. We know that every partnership is different - from stage, modality, therapeutic area, and culture. We have the skill, capabilities, and know-how to bring a holistic suite of models to life to continuously meet your needs. Let's grow together!

Participants

Presenter: Laura Lane - VP Lilly Ventures , European Head, Eli Lilly & Co

Pharma company presentation: Boehringer Ingelheim

11:30 - 11:45
Therapeutic Insights

Location: Room K2

We strive to improve the health of humans and animals - for generations. We work together with integrity and are guided by a shared purpose that defines who we are and what we do

Participants

Presenter: Detlev Mennerich - Global Head of Business Development & Licensing, Boehringer Ingelheim

"Blooming": Europe's ATMPs - leading the way in advanced therapy

11:30 - 12:00
Ecosystem Innovation

Location: Exhibit Hall Stage

This session will explore opportunities for biotech companies to develop and implement Advanced Therapy Medicinal Products (ATMPs) across Europe. Leading experts from key European hubs will discuss their collaborative efforts to enhance the visibility of European ATMP innovation and attract increased funding. By sharing insights and best practices, the session aims to foster a unified approach to addressing challenges in ATMP development, including clinical, financial, and workforce training issues. Attendees will gain a comprehensive understanding of the current landscape and future directions for advancing ATMP development in Europe.

Participants

Moderator: Anna-Pia Papageorgiou - Policy Officer, Health Innovations & Ecosystems, DG Research & Innovation, European Commission

Panelist: Marzena Flasz-Baron - Business Development Manager, CGT Catapult

Panelist: David Honba - COO, BioWin

Panelist: Kristina Levan - Director, Sahlgrenska ATMP Center, ATMP Sweden

Pharma company presentation: Servier

11:45 - 12:00
Therapeutic Insights

Location: Room K2

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier's long-term vision applies to its partnership philosophy. With €5.3Bn of revenue in 2023 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China. Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

Participants

Presenter: Anne Dagallier - Director Business Development Global Lead Oncology, Servier

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Lunch

12:00 - 14:00
Lunch

Pharma company presentation: Almirall

12:00 - 12:15
Therapeutic Insights

Location: Room K2

We are a pharmaceutical company committed to research and development of medicines for patients around the world.

Participants

Presenter: Ines Font - Director, Licensing Transaction, Almirall

"All for You": Transforming patient care with Intratumoral Therapy

12:30 - 13:00
Therapeutic Insights

Location: Exhibit Hall Stage

This session will explore the transformative potential of intratumoral therapies, including local immune activators, oncolytic viruses and radioenhancers, in revolutionizing cancer treatment. As these novel treatments face unique challenges in drug delivery and clinical adoption, the role of venture capital investment becomes critical. Collaboration with small and medium-sized enterprises is essential to advance innovation, overcome barriers, and accelerate the development of intratumoral therapies. This discussion will emphasise how strategic investments and collaborations have been a springboard to drive growth in this emerging field and unlock the potential to transform the standard of care for cancer patients.

Participants

Moderator: Linda Pullan - Business Development Consultant, Founder, Pullan Consulting

Panelist: Stephen Pitt - Global Head of External Innovation, Interventional Oncology, Johnson & Johnson

Panelist: Cristiana Pires - CEO, Asgard Tx

A day in the life of an experienced dealmaker

13:00 - 13:45
Business of Biotech

Location: Room K1

Gain insights from leading pharma and venture investors on navigating the dealmaking landscape and standing out in the current climate. Discover strategies, trends, and key considerations for successful partnerships. Join this session to learn how to thrive in today's competitive environment and drive impactful collaborations.

Participants

Moderator: Evonne Sepsis - Founder and Managing Director, ESC Advisors

Moderator: Anton Gueth - Managing Director, EVOLUTION Life Science Partners

Panelist: Chris Brown - Executive Director, GSK

Panelist: Roy Hardiman - Chief Business and Legal Officer, Alumis

Panelist: Rainer Strohmeier - Managing Partner, Wellington Partners

Panelist: Nathalie ter Wengel - European Lead Worldwide Business Development and Global Scouting Team Leader, Pfizer

Precision medicine – a systems shift: Prospects and challenges: how do we get there?

13:00 - 13:30
Therapeutic Insights

Location: Exhibit Hall Stage

Precision medicine represents a paradigm shift in healthcare, moving from a one-size-fits-all approach to personalized treatments based on an individual's genetic, environmental, and lifestyle factors. This session will explore the prospects of precision medicine, highlighting the technological, regulatory, and implementation challenges that must be overcome to integrate these advancements into the routine healthcare setting.

Participants

Moderator: Barnaby Pickering - Senior Writer - Medtech Insight, RHA Communications

Panelist: Anna Wedell - Professor, Senior consultant, Director PMCK, Karolinska Institutet

Oncology: TargTex S.A.

13:00 - 13:15
Company Presentations: Room K18

Location: Room K18

TargTex is a pioneering biotechnology company dedicated to the development of innovative therapeutic approaches for life-threatening diseases. Our primary focus is on oncology and cardiovascular indications, with a special emphasis on exploring the calcium channel TRPV2 as a novel therapeutic target. Our lead candidate is a groundbreaking treatment for Glioblastoma (GBM), the most common and aggressive type of primary brain cancer. GBM is one of the most challenging cancers to treat due to its heterogeneity, highly invasive nature and resistance to conventional therapies. Our lead treatment aims to address these challenges through a precision delivery approach, based on proprietary hydrogel nano-formulation carrying a small molecule targeting the TRPV2 calcium channel. With a potential seamless integration as part of the standard of care, preclinical studies have demonstrated that the lead product can eradicate the tumour, without signs of toxicity and systemic off-target exposure. The pre-clinical data and clinical development plans were validated at a pre-IND meeting with the FDA, providing a clear regulatory path for development. The company already engaged top tier clinical sites in Spain, France and USA to establish a phase 1/2a clinical trial in recurrent patients. Beyond Glioblastoma, TRPV2 has been implicated in cancer cell proliferation, migration, and survival and presents as a promising target for a range of oncological conditions. In addition, TRPV2 is involved in cardiac muscle function and its role has been clinically explored in cardiovascular indications such as heart failure. With a strong focus on TRPV2 and a promising lead candidate for Glioblastoma, our R&D efforts are focused on leveraging TRPV2 allosteric modulation to create a pipeline of therapies that address high unmet medical needs, aiming to develop first-in-class new medicines that make a significant impact on patients' lives and global health.

Participants

Presenter: Joao Seixas - CEO, TargTex S.A.

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Cell and Gene Therapies: CombiGene AB

13:00 - 13:15

Company Presentations: Room K12

Location: K12

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments. Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties. CombiGene has a team of very knowledgeable and experienced professionals, as well as solid, longstanding experience from the international pharma industry and the biotech arena, together with a thorough knowledge of different aspects of gene therapy. This combination of experience and expertise allows CombiGene, together with a network of selected external partners who complement CombiGene's internal expertise, to conduct ground-breaking gene-therapeutic development very effectively.

Participants

Presenter: Peter Ekolind - CEO, CombiGene AB

Oncology: Abion

13:15 - 13:30

Company Presentations: Room K18

Location: Room K18

Abion | Leading the Future of Oncology: First-in-Class Claudin-3 Targeting Antibody and Our Pan-Cancer Antibody-Cytokine Fusion Platform Beyond ADC

In oncology, ABION is advancing ABN202, an innovative antibody-cytokine fusion protein utilizing Interferon- β mutein technology, designed to provide exceptional anti-tumor efficacy. This novel platform not only enhances treatment options beyond traditional ADCs but also has the potential to synergize effectively with immune checkpoint inhibitors, establishing it as a versatile solution for advanced cancer therapies. Following this, ABN501, a first-in-class anti-Claudin-3 monoclonal antibody, is being developed to provide therapeutic options for various cancers, as the Claudin family has recently gained focus and popularity.

Participants

Presenter: Kyungeui Park - Director, Abion Inc

Cell and Gene Therapies: Neuracle Genetics

13:15 - 13:30

Company Presentations: Room K12

Location: K12

Neuracle Genetics, a clinical stage biotechnology company, is committed to improving patients' lives by harnessing the curative potential of gene therapy. We are developing innovative AAV gene therapy product candidates to treat retinal and neurological diseases with significant unmet needs. Leveraging our proprietary technologies, our product candidates are designed and optimized for safety and efficacy, with the goal of providing broader access to patients.

Participants

Presenter: Sunwoo Kim - Head of Business Development, Neuracle Genetics

"Waiting for Magic": European Health Data Space (EHDS): Uniform access to European healthcare data for research and AI

13:30 - 13:45

Ecosystem Innovation

Location: Exhibit Hall Stage

The upcoming EHDS2 regulation, set to replace national laws that control healthcare data usage for research within the EU, aims to standardize cross-border access to healthcare data across the EU for both academic and commercial purposes. Accessing data remains a complex process due to GDPR legislation, involving multiple steps such as data availability queries, processing data access applications, and releasing pseudonymized data for Secure Processing Environments (SPE), federated data analysis or as anonymised format.

For data sources, this regulation requires providing data descriptions to the HealthData@EU portal, enabling researchers to find suitable data sources for their projects, as well as to reply data queries. As data sources become more accessible, the volume of data availability and data access applications is expected to increase significantly. Therefore, it is crucial to automate and optimize current, often manual, processes to meet the EHDS-defined time limits for responses and to keep track of work hours and other resources used in project level.

BC Platforms has developed various AI-enhanced software tools to support data sources, such as university hospitals and National Contact Points, in complying with the forthcoming EHDS requirements e.g. for meta data descriptions and data quality labelling, complex feasibility queries, data access application and approval handling, data anonymisation and data release to SPEs. For researchers and AI model developers, BC Platforms offers advanced data analysis software operating within a Secure Processing Environment (SPE), capable of tracking hardware or cloud costs by project.

BC Platforms collaborates with major healthcare data integrator companies to deliver solutions ranging from individual hospital implementations to national-scale systems.

Participants

Panelist: Timo Kanninen - CSO and co-founder, BC Platforms

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Oncology: Galapagos

13:30 - 13:45

Company Presentations: Room K18

Location: Room K18

We are a biotechnology company with operations in Europe and the U.S. dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules and cell therapies in oncology and immunology. With capabilities from lab to patient, including a decentralized cell therapy manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders.

Participants

Presenter: Akis Andrianos - Director, Business Development, Galapagos

Cell and Gene Therapies: FibroBiologics

13:30 - 13:45

Company Presentations: Room K12

Location: K12

Based in Houston, FibroBiologics is a cell therapy and regenerative medicine company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. .

Participants

Presenter: Pete OHeeron - Founder & CEO, FibroBiologics

Oncology: RS Oncology LLC

13:45 - 14:00

Company Presentations: Room K18

Location: Room K18

RS Oncology is a private clinical stage biotechnology company based in Cambridge, MA with a mission to leverage new scientific discoveries to develop meaningful therapies against the most aggressive cancers. RSO's therapeutic pipeline is focused on modulating mitochondrial pathways that drive diseases of oxidative stress, with a primary focus on cancer. Our lead program, RSO-021, is a novel first-in-class, first-in-human small molecule that irreversibly binds mitochondrial peroxiredoxin 3 (PRX3) through covalent adduction of the active site. PRX3 is a new oncology target shown in preclinical models to support tumor cell escape from apoptosis, ferroptosis and promote proliferation. RSO-021 recently met its primary endpoint of safety and tolerability in Phase 1 testing (and showed efficacy) and is currently being evaluated in a multi-arm dose expansion Phase 2 clinical trial in the UK. In translational studies RSO-021 reduces the expression of pro- metastatic epithelial to mesenchymal (EMT) genes, induces apoptosis of tumor explants and alters the immune profile of the tumor microenvironment. In addition, RSO is developing a pipeline of systemic PRX3 inhibitors currently in the IND enabling stage.

Participants

Presenter: Jarrett Duncan - CEO, RS Oncology LLC

Cell and Gene Therapies: Cellevate

13:45 - 14:00

Company Presentations: Room K12

Location: K12

Cellevate AB is a biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell and gene therapy and novel vaccines. Our 5-year goal is to transform upstream bioprocessing with our sustainable ground-breaking cellulose based nanofiber microcarriers, produced by proprietary methods for industrial biomanufacturing of novel biotherapies. We currently employ 15 FTEs at our production facility in Lund, Sweden. In 2024/2025 we will establish a US office & expand in other European countries with large numbers of CDMOs and biopharma bioproduction such as Germany, Austria, Switzerland, Belgium Netherlands, France and UK. We estimate to grow to 60 FTEs in 2026. With validations performed, Cellevate is strategically positioned to advance to its next phase of growth and commercialization. The first product portfolio, Cellevat3dTM nanofiber microcarriers has a global commercial launch at this event, BIO-Europe, November, 2024. The product portfolio is designed to improve yield and productivity of viral vectors production in gene therapy applications, thereby increasing patient accessibility to these costly therapeutics. Cellevat3dTM nanofiber microcarriers provide unparalleled surface area for cell culturing, mimic accurately the human body's extracellular environment and are scalable from R&D to commercial manufacturing.

Participants

Presenter: Laura Chirica - CEO, Cellevate

"Two for the Price of One!": The ADC arena

14:00 - 14:45

Therapeutic Insights

Location: Room K2

Big pharma's ADC land grab has driven a multi-billion-dollar dealmaking frenzy. This session explains what the excitement is all about, providing insights into the current ADC landscape, latest innovations and challenges facing ADC development. Hear perspectives on the future of ADCs and their potential the reshape the paradigm of precision medicine.

Participants

Moderator: Melanie Senior - Writer & Analyst, Nature, Evaluate, IN VIVO

Panelist: Khaterreh Ahmadi - Head of Search and Evaluation Team, European BD&L Hub, MSD

Panelist: Joachim Albers - Director, Search & Evaluation Lead, BD Oncology, Merck

Panelist: Sonal Patel - VP of Oncology Scientific innovation, Johnson & Johnson Innovation

Panelist: Michael Pehl - CEO, Adcendo

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"Pay The Price": Reimbursement - is there now a single HTA procedure in the European Union?

14:00 - 14:45

Ecosystem Innovation

Location: Exhibit Hall Stage

In the European Union (EU), medicines are authorized centrally, but reimbursement is carried out at the national level: the EU member states conduct national assessment procedures for this purpose, known as health technology assessments (HTAs). Harmonization of these procedures is one of the most important innovations in the regulatory framework for medicines in Europe. From January 2025, a common clinical assessment will come into force in the EU. This will be introduced gradually, starting with cancer medicines (including orphan oncology drugs) and ATMPs. A whole series of important EU regulations came into force in 2024. Currently, national regulations are being adapted to the new European procedure in the EU member states. And now, in the fall of 2024, many details regarding the implementation and execution of the new procedure are clarified. This panel will discuss how small and large biopharmaceutical companies need to adapt to the new procedure to reach Europe's patients quickly and successfully with their innovative therapies.

Participants

Moderator: Fabian Berkemeier - Managing Director, IGES Institut

Panelist: Niklas Hedberg - Chief Pharmacist, The Swedish Dental and Pharmaceutical Benefits Agency (TLV)

Panelist: Sofia Heigis - CEO, Oncopeptides

Panelist: Gry Stine Kopperud - Nordic Value & Access Head, Novartis

Panelist: Alexander Natz - Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

"The Winner Takes It All": How to overcome the translational gap in Europe

14:00 - 14:45

Startup Spotlight

Location: Room K11

We will address the critical challenge of translating academic research into practical applications that benefit patients across Europe. Experts from various fields—including healthcare, policy-making, and patient advocacy—will discuss innovative strategies to enhance collaboration between researchers and healthcare practitioners. Key topics will include the importance of patient-centered research, effective communication of scientific findings, and the role of technology in facilitating access to information. Panelists will share current initiatives and explore frameworks for fostering partnerships that ensure research outcomes are effectively implemented in clinical settings.

Participants

Moderator: Chris Maggos - Managing Director, Cohesion Bureau

Panelist: Hanne Mette Dyrllie Kristensen - VP Business development, investor relations & collaboration, The Life Science Cluster

Panelist: Daniel Forler - Director Business Development – New Platforms, Cardiology & Immunology, Pharmaceuticals Division, Bayer

Panelist: Lene Gerlach - Founder & Chair, Women in Life Science Denmark (WiLD)

Panelist: Ahmed Mohamed - Early Innovation Partnering Lead, Johnson & Johnson Innovation

Oncology: OncoLize BV

14:00 - 14:15

Company Presentations: Room K18

Location: Room K18

OncoLize: "Treating Tumors from the Inside" - OncoLize (Leiden, NL) develops injectable drug depots for localized, intra-tumoral injections. Based on successful pre-clinical data in Lung tumors and PDAC, and with clear cost-effective scale-up potential, the company is preparing its IMPD/IND and CT Phase I/II for pancreatic cancer and other indications. - The products are delivered into solid tumors using image guided endoscopes, catheters, and fine injection needles. Delivering generic chemo or novel drugs in this localized manner offers precision: a) 10-100x higher concentration at target with b) much smaller total doses and c) up to 1000x lower drug levels outside the tumor... Pre-clinical studies in established Pancreatic tumor and Lung tumor models have shown spectacular tumor growth inhibition with evidence of immune activation from 'cold' to 'hot'. Current work is focused on non-clinical safety and tox studies and scale-up/CMC to clinical grade products. 3. As 90% of all cancers are solid tumors, 70% of all tumors are diagnosed before metastasis, and the mean age of patients is 66 years of age when first diagnosed, local and sustained release offers a powerful proposition to treat patients with better outcome, far less side effects and making it Triple A: Affordable and Accessible for All. 4. OncoLize features a highly experienced founders' team which closed a Seed A round of €1,6 million, and is preparing a Seed B round of €1 million. We aim to raise a Series A €10+ mln by mid 2025 to achieve CT phase I/II studies in up to 3 indications with a pipeline of multiple product market combinations, scale-up of products for clinical trials and early commercialization potential. 5. Patents from 2017 have been granted in USA, China and Japan, with EU in final stages and more to come. 6. The company also seeks to partner for impact in less privileged communities, so collaboration with NGO's and impact investors is as much welcomed as VC-backed funding.

Participants

Presenter: Mike G.W. de Leeuw - CEO & Founder, OncoLize BV

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Cell and Gene Therapies: TiCARos

14:00 - 14:15

Company Presentations: Room K12

Location: K12

TiCARos is a clinical-stage biotech developing next-generation CAR-T cell therapies aimed at treating hematologic malignancies and solid tumors. Our foundation lies in our three proprietary platforms that drive innovation and improve therapeutic outcomes. Central to our approach is the CLIP (CLamping-based Immunological Potentiation) CAR platform, a CAR backbone modification technology that enhances the formation and stability of the immunological synapse. This platform significantly boosts the longevity and efficacy of CAR-T cell therapies, allowing for more effective engagement and elimination of cancer cells. In addition to CLIP, TiCARos is pioneering other transformative technologies, including the Converter CAR and Switchable CAR platforms. Converter CAR technology is designed to amplify T-cell activation, thereby increasing the therapeutic potency and durability of CAR-T treatments. Switchable CAR technology provides precise control over CAR-T cell activity, allowing for real-time modulation of the immune response to enhance safety and reduce off-target effects. Together, these platforms offer a comprehensive approach to developing safer, more effective cancer therapies that can be tailored to meet the specific needs of different tumor types. TiCARos is led by a team of seasoned industry experts and scientific leaders who bring decades of experience in cell therapy and immunotherapy. Our Chief Technology Officer, Prof. Kyungho Choi, is a renowned expert in the field of immuno-oncology, with an extensive background in CAR-T cell research and development. Through strategic partnerships with leading research institutions and biotechnology companies, TiCARos is well-positioned to bring our next-generation CAR-T therapies to the forefront of the global oncology market.

Participants

Presenter: Suhong Daniel Kim - Associate Director, Business Development, TiCARos

Oncology: Cleara Biotech B.V.

14:15 - 14:30

Company Presentations: Room K18

Location: Room K18

Cleara Biotech B.V. (www.clearabiotech.com) develops therapies diseases caused by scarred cells, with a focus on late-stage, metastatic cancer. Based on a patented MoA, Cleara nominated a development candidate, CL04183. CL04183 is especially potent and selective against biomarker-positive types of cancer in mouse models and 3D cancer patient-derived organoids. Cleara is within 12-18 months from the clinic, with IMPD -enabling GLP-TOX and CMC funded and scheduled for completion in Q1-2 2025. Scarred cancer cells not only continue to divide, but are highly invasive, and generally more resistant to treatment. Cleara identified these cells to show elevated levels of the proteins PML and a phosphorylated form of the guardian protein p53. Through its cell-penetrating peptide (CPP) platform technology Cleara integrated cycles of structural, biochemical and cellular discovery to ultimately nominate CL04183. CL04183 is unique in that it is optimized around binding this (phosphorylated) complex and triggering transcription-independent apoptosis. Importantly, CL04183 is also highly effective when p53 is mutated, as is the case in many metastatic types of cancer. Cleara is based in Utrecht, the Netherlands and closely tied to the University Medical Center, giving it wide access to research, clinical data and patients. It has established and highly experienced Management, Board and Development teams in the Netherlands, Germany, Switzerland and the US. Cleara is already funded by Apollo Health Ventures (www.apollo.vc) which is the founding VC, as well as other life science focused groups, including Curie Capital (www.curiecapital.nl). Moreover, following stringent due diligence, Cleara is supported by public funds from the Regional Development Fund and the Dutch Government. All of these plan to participate in the Series A financing. For Ph1 and Ph2 trials against scarring-positive Colon, breast and ovarian cancer, Cleara is currently looking for Series-A financing.

Participants

Presenter: Peter de Keizer - Managing Director, Cleara Biotech B.V.

Cell and Gene Therapies: Aurion Biotech

14:15 - 14:30

Company Presentations: Room K12

Location: K12

Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech. Its first candidate, AURN001, is for the treatment of corneal edema secondary to corneal endothelial disease, and the first clinically validated cell therapy for corneal care, having already received regulatory approval in Japan. From a single donor, Aurion Biotech can reproduce enough fully differentiated corneal endothelial cells to treat up to 1,000 eyes. This allogeneic cell therapy does not require immune type matching, nor any form of gene editing. Consequently, company leadership believes AURN001 may become the first "mass market" allogeneic cell therapy. Aurion Biotech has completed enrollment and dosing of its Phase 1 / 2 clinical trial in the U.S. and Canada and hopes to have topline data available in early 2025. Recently, the U.S. F.D.A. granted both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for AURN001. The Company believes these designations speak to the promise and potential of AURN001 to address a massive, global unmet need. Privately held, Aurion Biotech is backed by Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.

Participants

Presenter: Greg Kunst - CEO, Aurion Biotech

Immuno-Oncology: BioInvent International AB

14:30 - 14:45

Company Presentations: Room K18

Location: Room K18

BioInvent International AB (publ) (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1b and 2a trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

Participants

Presenter: Sylvie Ryckebusch - CBO, BioInvent International AB

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Cell and Gene Therapies: Mediphage Bioceuticals, Inc.

14:30 - 14:45

Company Presentations: Room K12

Location: K12

Mediphage, a Toronto-based biotechnology company, has developed a minimal and back-bone free, high-fidelity, linear covalently closed (LCC) DNA vectors, called ministring DNA (msDNA), which it produces through its proprietary, scalable E. coli-based manufacturing process. msDNA can be used as high-quality starting material in viral vector production (rAAV, lentivirus) and mRNA vaccines and therapeutics and as drug substance in gene therapy and gene editing for therapeutics development. Product differentiation of msDNA's 'Plug-and-play' genetic medicine platform and its rapid, scalable production process has generated growing demand for msDNA evaluation across the therapeutics and biotools industry. Mediphage has a number of collaborations with pharma partners, biotech companies, CDMOs, and research organizations evaluating msDNA for various applications. Internally, Mediphage is developing redosable and durable non-viral gene therapy assets for liver, CNS, and ophthalmic disorders.

Participants

Presenter: Alvaro Amorrrortu - CEO, Mediphage Bioceuticals, Inc.

Immunology: Ziphius

14:45 - 15:00

Company Presentations: Room K18

Location: Room K18

Ziphius, founded in 2019, is a Belgian-based pharmaceutical company with a mission to reduce the global impact of infectious and rare genetic diseases. Through its innovative Platform Technology utilizing self-amplifying RNA (saRNA), the company develops safe and effective biopharmaceuticals, including prophylactic vaccines and gene supplementation therapies. Located in New York, USA and Zwijnaarde, Belgium. Ziphius focuses on combining self-amplifying saRNA technologies with advanced lipid formulations for targeted delivery. Their primary emphasis lies in the preclinical and early clinical phases, addressing prophylactic vaccines and protein-enhancement therapies for rare genetic disorders. The team consist of complementary highly dedicated experts with a strong entrepreneurial, scientific, clinical, managerial and pharmaceutical background. Ziphius focuses on two main areas: • Prophylactic Platform: In this domain, Ziphius aims to develop medicines for protecting individuals against commonly occurring infectious pathogens, including viruses and bacteria. The self-amplifying (sa) RNA technology involves an RNA backbone, a gene encoding a specific antigen/polypeptide/protein, and a lipid-rich envelope (lipid nanoparticles or LNP). Post-injection, this envelope fuses with the patient's cell membrane, releasing synthetic saRNA molecules into the cell. These molecules instruct cells to produce the encoded antigen/polypeptide/protein, triggering a robust and long-lasting immune response. Ziphius meticulously tests combinations of RNA backbones and lipid envelopes to select the optimal combination for developing saRNA-based vaccines. •

Therapeutics : This department seeks therapies to alleviate symptoms and enhance the quality of life for patients. Utilizing saRNA technology with tailored delivery vehicles. Ziphius aims to reduce side effects and achieve targeted delivery. The technology offers the potential for increased protein production and persistent expression.

Participants

Presenter: Chris Cardon - CEO, Ziphius

Cell and Gene Therapies: Affinia Therapeutics

14:45 - 15:00

Company Presentations: Room K12

Location: Room K12

Affinia Therapeutics is pioneering a new class of rationally designed gene therapies to treat rare and prevalent diseases. The Affinia Rationally designed Therapeutics (ART) platform synergistically improves the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches

Participants

Presenter: Rick Modi - CBO, Affinia Therapeutics

"Merry-Go-Round": Impact of the evolving pharmaceutical legislation on investor and company strategies in the life science ecosystem

15:00 - 15:30

Business of Biotech.

Location: Exhibit Hall Stage

Explore the transformative impact of evolving pharmaceutical legislation on investor and company strategies within the life science ecosystem. Delve into the intricate interplay between regulatory changes, market dynamics, and strategic decision-making, as industry experts navigate the path forward amidst shifting landscapes and emerging opportunities.

Participants

Moderator: Claire Skentelbery - Director General, EuropaBio

Panelist: Fabrizio Conicella - VP - Center of Open Innovation & Competence, Chiesi Group

Panelist: Joao Incio - General Partner, Biovance Capital

Panelist: Wojciech Nowak - Group Senior Director, Global Governmental and Public Affairs, Novartis International

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"Just a Notion": Strategic partnerships and future opportunities in radiopharma

15:00 - 15:45
Therapeutic Insights

Location: Room K2

Explore the burgeoning radioligand therapy landscape, with its multiple innovation areas and lucrative partnerships. Delve into the unique advantages of targeted radiotherapies, recent deals, and uncover the strategic opportunities that lie ahead.

Participants

Moderator: Melanie Senior - Writer & Analyst, Nature, Evaluate, IN VIVO

Panelist: Anja Bitterwolf - Business Development & Licensing Manager, Debiopharm International SA

Panelist: Marcel Reichen - Exec. Director, Search and Evaluation, Novartis

Panelist: Serge Sagodira - CBO, Ariceum Therapeutics

Panelist: Emanuele Ostuni - CEO, ARTBIO Inc.

"Take a Chance on Me": Startup spotlight pitch competition

15:00 - 17:00
Startup Spotlight

Location: Room K11

The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe audience. A panel of esteemed judges will evaluate the pitches and select the winners.

Startup Finalists: *Presenting in order

Harmonic Discovery: Oncology

Kadence Bio: Neurology & Rare Diseases

Loma Therapeutics: Oncology

Nia Health GmbH: Digital Health

Sarcomatrix Therapeutics Corp.: Neurology & Rare Diseases

StemSight: Cell & Gene

Theratrane S.A.: Oncology

V4CURE: Neurology & Rare Diseases

Participants

Moderator: Benjamin Holinski - Chief of Staff, Bayer Pharmaceuticals

Judge: Ayokunmi Ajetunmobi - Director of Venture Development, Pioneer Group

Judge: Peter Heinrich - Co-founder, Managing Director, Sinfonie LSM

Judge: Chelsea Ranger - Founder, C. Ranger Consulting

Judge: Dominik Ruettinger - Global Head Research and Early Development Oncology, Bayer

Presenter: Anna Cichonska - Director of Data Science and Head of European Operations, Harmonic Discovery

Presenter: John Boghossian - CEO, Kadence Bio

Presenter: Stephanie Holstein-Rønsbo - Founder and COO, Loma Therapeutics

Presenter: Tobias Seidl - CEO and Founder, Nia Health GmbH

Presenter: David Craig - CEO, Sarcomatrix Therapeutics Corp.

Presenter: Laura Koivusalo - CEO and Founder, StemSight

Presenter: Sonia Escaich - CEO, V4CURE

Presenter: Jonathan Ward - CEO, Theratrane S.A.

"Indestructible": Why is AI crucial for the future of the biopharma industry?

15:30 - 16:00
Business of Biotech

Location: Room K1

Explore why AI is not just a trend but a transformative force shaping the future of healthcare and biopharma. Gain insights into its profound implications for research, development, and patient care.

Participants

Moderator: Hubert Birner - Managing Partner, TVM Capital

Panelist: Denis Dubuy - Director of Corporate Development, Owkin

Panelist: Verena Schustereder - Customer Engineering Manager, Google Europe

"Mamma Mia": Transatlantic reflections - assessing US policy impacts on the European biopharma ecosystem

15:45 - 16:15
Business of Biotech.

Location: Exhibit Hall Stage

Join us for a fireside chat where experts assess the impact of US policies on the European life sciences ecosystem. Delve into the regulatory landscape, market dynamics, and strategic implications, exploring how transatlantic influences shape the future of biopharma innovation and collaboration.

Participants

Moderator: Crystal Kuntz - Senior VP, Health Policy & Reimbursement, Biotechnology Innovation Organization (BIO)

Panelist: Duane Schultness - CEO, Vital Transformation

Panelist: Christopher Uhde - Senior Pharma & Biotech Equity Analyst, SEB

SESSIONS

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

"I Have a Dream": AI for drug discovery

16:00 - 17:00
Business of Biotech

Location: Room K1

Hear how AI algorithms are reshaping the landscape, accelerating the identification and development of novel therapeutics. Learn from industry experts about the latest advancements, challenges, and promising opportunities in this frontier of innovation.

Participants

Moderator: Maria Luisa Pineda - Vice Chair, Cofounder and Board Member, Envisagenics

Panelist: Lovisa Afzelius - General Partner, Flagship Pioneering

Panelist: Stephan Brock - CEO, Molecular Health

Panelist: Michelle Chen - CBO, Insilico Medicine

Panelist: Tim James - VP, Head of In Silico R&D, Evotec

Panelist: Hartmut Juhl - CEO, Indivumed GmbH

Panelist: Nikolaus Krall - EVP Precision Medicine, Exciencia

Panelist: Rogier Rooswinkel - General Partner, Forbion

"Under Attack": Can cell & gene therapy revolutionise the rules of healthcare?

16:00 - 16:45
Therapeutic Insights

Location: Room K2

Delve into the groundbreaking potential of cell and gene therapy and its potential to reshape healthcare as we know it. Explore the transformative impact of these therapies on disease treatment and prevention, challenging conventional medical paradigms. Discover how these innovative modalities are rewriting the rules of healthcare for a brighter future.

[Cell and gene therapy: Insights](#)

Participants

Moderator: Romain Bonnot - Principal, ZS Associates

Panelist: Celine Carlet - VP, Head of Transactions, Galapagos

Panelist: Reagan Jarvis - CEO, Scientific founder, Anocca

Panelist: Michael May - President & CEO, CCRM

Break and breathe

16:30 - 16:45
Relax and Learn

Location: Exhibit Hall Stage

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

Sustainability Focus Area: Social Responsibility

"Why Did it Have to Be Me?": AI for diagnosis

17:00 - 17:45
Business of Biotech

Location: Room K1

Explore how AI-driven technologies are revolutionizing medical diagnostics, enhancing accuracy, efficiency, and patient outcomes. Gain valuable insights from experts on the latest developments, challenges, and future prospects in leveraging AI for diagnostic purposes.

Participants

Moderator: Bora Erdemli - Principal, ZS Associates

Panelist: Andrea Gisle Joosen - Member of the board, Zühlke Group

Panelist: Ralf Huss - Managing Director, BioM

Panelist: David Krummen - Co-founder and Professor of Medicine, Vektor Medical and UC San Diego, Cardiology

Panelist: Andrea Riposati - CEO, Dante Labs

Panelist: Miha Stajdohar - CTO and Co-founder, Genialis

"I've Been Waiting for You": Rise of novel cardiometabolic therapies

17:00 - 17:45
Therapeutic Insights

Location: Room K2

This session delves into the future of cardiometabolic therapy. As the buzz around GLP-1 receptor agonist-based drugs stabilises, the sector is already on the lookout for novel cardiometabolic treatment modalities. Dive into the collaborations focusing on cardiometabolic therapies, the implications and partnering strategies, in the evolving landscape of cardiometabolic care.

Participants

Moderator: Ed Saltzman - Senior Strategic Advisor, Humanity

Panelist: Peng Leong - CBO and Head of Brain Aging, BioAge

Panelist: Brett Haumann - Venture Partner, SV Health Investors LLP

Panelist: Birgit Steckel-Hamann - Senior Director - External Innovation Cardiometabolic Health, Eli Lilly & Company

EBD Bubbly Reception

17:30 - 18:30
Live Networking

Join us at the EBD booth (booth #95A) to celebrate the 30th Anniversary of BIO-Europe with the return of the end-of-day sparkling wine reception.

Evening networking reception

19:00 - 23:00

Location: Nacka Strand Möten & Event

Time: 19:00 - 23:00

This unique site of a regenerated automotive factory, known as Bilfabriken to Stockholm locals, creates the perfect setting to celebrate BIO-Europe's 30th anniversary!

- Enjoy a delightful Swedish tasting menu, served standing and buffet style. It is complemented by local beers, wines and soft drinks.
- Network in dedicated and inviting lounge areas, perfect for more relaxed conversations.
- Or dance to the beats of DJ Simon, a familiar favourite for many delegates.

SCHEDULE

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12	RELAX AND LEARN	LUNCH	BUSINESS OF BIOTECH.	STARTUP SPOTLIGHT	LIVE NETWORKING
06:00	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run
07:00	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)
08:00	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)	08:45 - Partnering: one-to-one meetings (8:00 - 18:30 CET)
09:00	09:30 - "Dressed for Success": Evolution of leadership over 30 years	09:00 - "Keep This Fire Burning": Innovate or acquire? Strategic choices for filling pharma pipelines	09:00 - "Live and Learn": Navigating biotech's clinical development challenges: Diverse strategies for thriving in 2024's complex landscape	09:00 - Oncology: Tempus AI, Inc. 09:15 - Oncology: Spirea 09:30 - Oncology: Etnova Therapeutics Corp. 09:45 - Oncology: Tenboron Oy	09:00 - Immunology: HanchorBio Inc. 09:15 - Immunology: Txinno Bioscience Inc. 09:30 - Immunology: Myeloid Therapeutics 09:45 - Immunology: Accession Therapeutics					

SCHEDULE

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12	RELAX AND LEARN	LUNCH	BUSINESS OF BIOTECH.	STARTUP SPOTLIGHT	LIVE NETWORKING
10:00	10:15 - "Celebration" Turning the tables: 40 years of industry insight – Mike Ward, the interviewer, becomes the interviewee!	10:00 - "Rise and Shine" - Immunology: The next surge on the horizon? 10:30 - Pharma company presentation: Novartis AG 10:45 - Pharma company presentation: Sanofi	10:00 - Navigating the biopharma services landscape: Current trends and future perspectives 10:30 - "Always Have, Always Will": Creating value by excellence in CMC development	10:00 - Oncology: Osmol Therapeutics, Inc.	10:00 - Immunology: VacV Biotherapeutics Limited	10:30 - Break and breathe				
11:00	11:00 - "Sayit": The Flot.bio show at BIO-Europe: In conversation with Lovisa Afzelius, Flagship Pioneering	11:00 - Pharma company presentation: MSD 11:15 - Pharma company presentation: Eli Lilly & Company 11:30 - Pharma company presentation: Boehringer Ingelheim 11:45 - Pharma company presentation: Servier	11:00 - "A Thing About You": The ecosystem is the product: Unlocking Canada's life sciences advantages in AI and regenerative medicine 11:30 - "Blossoming": Europe's ATMPs - leading the way in advanced therapy							

SCHEDULE

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12	RELAX AND LEARN	LUNCH	BUSINESS OF BIOTECH.	STARTUP SPOT-LIGHT	LIVE NETWORKING
12:00		<p>12:00 - Pharma company presentation: Almirall</p> <p>12:30 - "All for You": Transforming patient care with Intratumoral Therapy</p>					12:00 - Lunch			
13:00	<p>13:00 - A day in the life of an experienced deal-maker</p>	<p>13:00 - Precision medicine – a systems shift: Prospects and challenges: how do we get there?</p>	<p>13:30 - "Waiting for Magic": European Health Data Space (EHDS): Uniform access to European healthcare data for research and AI</p>	<p>13:00 - Oncology: TargTex S.A.</p> <p>13:15 - Oncology: Abion</p> <p>13:30 - Oncology: Galapagos</p> <p>13:45 - Oncology: RS Oncology LLC</p>	<p>13:00 - Cell and Gene Therapies: CombiGene AB</p> <p>13:15 - Cell and Gene Therapies: Neuracle Genetics</p> <p>13:30 - Cell and Gene Therapies: FibroBiologics</p> <p>13:45 - Cell and Gene Therapies: Cellevate</p>					

SCHEDULE

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12	RELAX AND LEARN	LUNCH	BUSINESS OF BIOTECH.	STARTUP SPOTLIGHT	LIVE NETWORKING
14:00		14:00 - "Two for the Price of One!": The ADC arena	14:00 - "Pay The Price": Reimbursement - is there now a single HTA procedure in the European Union?	14:00 - Oncology: OncoLize BV 14:15 - Oncology: Cleara Biotech B.V. 14:30 - Immunology: Biolnvent International AB 14:45 - Immunology: Ziphius	14:00 - Cell and Gene Therapies: TiCARos 14:15 - Cell and Gene Therapies: Aurion Biotech 14:30 - Cell and Gene Therapies: Mediphage Biocenticals, Inc. 14:45 - Cell and Gene Therapies: Affinia Therapeutics				14:00 - "The Winner Takes It All": How to overcome the translational gap in Europe	

SCHEDULE

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	THERAPEUTIC INSIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: ROOM K18	COMPANY PRESENTATIONS: ROOM K12	RELAX AND LEARN	LUNCH	BUSINESS OF BIOTECH.	STARTUP SPOTLIGHT	LIVE NETWORKING
15:00	15:30 - "Indestructible": Why is AI crucial for the future of the biopharma industry?	15:00 - "Just a Notion": Strategic partnerships and future opportunities in radio-pharma						15:00 - "Merry-Go-Round": Impact of the evolving pharmaceutical legislation on investor and company strategies in the life science ecosystem 15:45 - "Mamma Mia": Transatlantic reflections - assessing US policy impacts on the European biopharma ecosystem	15:00 - "Take a Chance on Me": Startup spotlight pitch competition	
16:00	16:00 - "I Have a Dream": AI for drug discovery	16:00 - "Under Attack": Can cell & gene therapy revolutionise the rules of health-care?				16:30 - Break and breathe				
17:00	17:00 - "Why Did it Have to Be Me?": AI for diagnosis	17:00 - "I've Been Waiting for You": Rise of novel cardiometabolic therapies								17:30 - EBD Bubbly Reception

SCHEDULE

DAY 2 - 05/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	THERAPEUTIC IN-SIGHTS	ECOSYSTEM IN-NOVATION	COMPANY PRE-SENTATIONS: ROOM K18	COMPANY PRE-SENTATIONS: ROOM K12	RELAX AND LEARN	LUNCH	BUSINESS OF BIOTECH.	STARTUP SPOT-LIGHT	LIVE NETWORK-ING
19:00	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception	19:00 - Evening networking re-ception

SESSIONS

DAY 3 - 06/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)

07:45 - 09:00

Location: **Stockholmsmässan**

Light Breakfast: **served until 10:45**

Partnering: one-to-one meetings (8:00 - 17:00 CET)

09:00 - 09:30

One-to-one meetings at BIO-Europe will be scheduled during the hours below:

Meetings on this day will start at **8:00 – 17:00 CET**.

Next Generation: SapiensBio

09:30 - 09:40

Company Presentations: Exhibit Stage

Location: Exhibit Stage

SapiensBio is a small data-driven technology-based drug discovery company with Headquarters in South Korea and an office in the USA. The company focus on the discovery of novel drug candidates for the treatment of severe (life threatening) diseases where there is a clear unmet medical need. We are integrating machine learning technology with wet lab experimental work to support the identification of novel therapeutic targets and to create novel chemical matter with drug like properties that can rapidly be converted in clinical candidates.

Participants

Presenter: Jose Freire - CEO, SapiensBio

Academic Innovator: Ingineeon

09:40 - 09:50

Company Presentations: Exhibit Stage

Location: Exhibit Stage

We at ingineeon develop the tools to form an unbeatable alliance with the most precise, efficacious and lasting force against diseases: our immune system. With our cytokine-based immunotherapeutics we can precisely modulate immune responses. This will allow for a therapeutic breakthrough in immunology, infectious diseases and autoimmunity. Our pipeline comprises first-in-class biologics as well as a cytokine-based platform biotechnology for advanced therapy medicinal products. Each of our compounds is based on scientific breakthrough innovations. Each of them has an unique Mechanism of Action with a therapeutic breakthrough potential in the respective indication. After generating a promising pipeline, a strong IP portfolio and promising data from our preclinical patients studies we are ready for the next big step: spin-off from the Technical University of Munich to become a clinical stage company in the coming few years.

Participants

Presenter: Julia Behnke - CEO, Ingineeon

Next Generation: PartitionBio

09:50 - 10:00

Company Presentations: Exhibit Stage

Location: Exhibit Stage

PartitionBio is a start-up R&D company that is active in the biotechnology & pharma sectors. The company has been operating since 2022 and is incorporated as a private limited company (UK company number 13421275). PartitionBio has its offices and laboratories on the Chesterford Research Park near Cambridge, and currently employs 9 full-time staff. Company vision and scientific background The past decade has seen an explosion of scientific insight into the role that biomolecular condensates play in biology, as well as into the physicochemical principles underlying their formation by liquid-liquid-phase-separation (LLPS) of biomolecules. PartitionBio's vision is to translate this emerging understanding into novel biomedical applications, particularly in the therapeutics space. The company's initial focus is on the identification of formulations that generate biomolecular condensates capable of enriching drug cargos and of delivering them across the membranes of target cells. The company aims to develop its recent discoveries in this area into a viable platform approach for the delivery of hard-to-deliver therapeutics (specifically large biology drugs) in a clinical context. Team & capabilities The team of scientists at PartitionBio combines expertise in a range of biomedically relevant disciplines, including synthetic chemistry, protein engineering, condensate & cell biology and high-content screening microscopy. We use this know-how to design, generate and interrogate libraries of peptidomimetic oligomers to discover novel condensate-forming formulations. Leadership Dr Niall Armes is the scientific founder of PartitionBio. In previous ventures TwistDx and Biocrucible he has pioneered the use of biomolecular condensates for the acceleration of enzyme kinetics in in vitro reaction systems, particularly for the isothermal amplification of DNA. PartitionBio is led by Managing Director Dr Olaf Piepenburg, formerly CSO of TwistDx

Participants

Presenter: Olaf Piepenburg - Managing Director, PartitionBio

Next Generation: MONCYTE Health

10:00 - 10:10

Company Presentations: Exhibit Stage

Location: Exhibit Stage

A novel personalized diagnostic test for optimal cholesterol-lowering therapy.

Monocyte is the next level decision making tool to revolutionize the treatment of high cholesterol and bring more health to patients.

Participants

Presenter: Tamara Alagirova - CEO, Monocyte

SESSIONS

DAY 3 - 06/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

Next Generation: LincSwitch Therapeutics, Inc.

10:10 - 10:20

Company Presentations: Exhibit Stage

Location: Exhibit Stage

LincSwitch is a drug discovery platform company specializing in long non-coding RNAs (lncRNAs). Our platforms explore the dark genome, emphasizing phenotypic outcomes, with the objective of achieving rapid and robust regulation of pharmaceutically relevant target genes. LincSwitch was co-founded this year by CEO Andrew Sandford, former President of ElevateBio Basecamp; Marvin Caruthers, PhD, Distinguished Professor at CU Boulder and co-founder of Amgen and Applied Biosystems; John Rinn, PhD, Professor at CU Boulder; and Olivia Scharfman, former Principal at SALT Fund.

Participants

Presenter: Olivia H Scharfman - Co-founder, Head of Business Development & Commercial Strategy, LincSwitch Therapeutics, Inc.

Next Generation: Blue Bee's Therapeutics

10:20 - 10:30

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Blue Bees Therapeutics is a biotechnology company founded in 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay.

This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG).

Company Presentations

10:30 - 10:40

Company Presentations: Exhibit Stage

Location: Exhibit Stage

Break and breathe

10:45 - 11:00

Relax and Learn

Location: Exhibit Hall Stage

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

Sustainability Focus Area: Social Responsibility

"Thank You for the Music": Key takeaways from BIO-Europe's 30th anniversary!

11:00 - 11:45

Business of Biotech

Location: Exhibit Hall Stage

Join us as we dive into a comprehensive recap of BIO-Europe 2024. Get a pulse on the event with highlights, fresh perspectives, key insights, and impactful takeaways from speakers and participants. Gear up for BIO-Europe 2025 as we welcome you to...Vienna!

Participants

Moderator: Millie Nelson - Editor of BioXconomy, Informa

Panelist: Cormac Sheridan - Journalist, Freelance

Panelist: Jonathan Smith - Biotech and Healthcare Correspondent, Mergermarket Ltd

Panelist: Christian Soschner - CEO, CS Life Science Invest

Lunch

12:00 - 14:00

Business of Biotech

Closing reception : Thank you Stockholm! Vienna calling!

16:00 - 17:30

Location: Booth #97

Time: 16:00 - 17:30

SCHEDULE

DAY 3 - 06/11/2024

BIO-Europe

Europe's premier partnering event
November 3–5, 2025 | Vienna, Austria
November 11–12, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	COMPANY PRESENTATIONS: EXHIBIT STAGE	RELAX AND LEARN
07:00	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)
09:00	09:00 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	09:30 - Next Generation: SapiensBio 09:40 - Academic Innovator: Ingineeon 09:50 - Next Generation: PartitionBio 09:00 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	09:00 - Partnering: one-to-one meetings (8:00 - 17:00 CET)
10:00		10:00 - Next Generation: MONCYTE Health 10:10 - Next Generation: LincSwitch Therapeutics, Inc. 10:20 - Next Generation: Blue Bee's Therapeutics 10:30 - Company Presentations	10:45 - Break and breathe
11:00	11:00 - "Thank You for the Music": Key takeaways from BIO-Europe's 30th anniversary!		
12:00	12:00 - Lunch		
16:00	16:00 - Closing reception : Thank you Stockholm! Vienna calling!	16:00 - Closing reception : Thank you Stockholm! Vienna calling!	16:00 - Closing reception : Thank you Stockholm! Vienna calling!